Office de la Propriété Intellectuelle du Canada
Un organisme d'Industrie Canada

Canadian Intellectual Property Office
An agency of Industry Canada

CA 2425672 A1 2003/04/11

(21) 2 425 672

(12) DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION

(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2001/10/10
(87) Date publication PCT/PCT Publication Date: 2003/04/11
(85) Entrée phase nationale/National Entry: 2003/04/11
(86) N° demande PCT/PCT Application No.: EP 2001/011701
(87) N° publication PCT/PCT Publication No.: 2002/030428
(30) Priorité/Priority: 2000/10/13 (100 50 663.1) DE

(51) Cl.Int.^{7}/Int.Cl.^{7} A61K 31/4985, A61K 31/519

(71) Demandeur/Applicant:
GRUNENTHAL GMBH, DE

(72) Inventeurs/Inventors:
SUNDERMANN, BERND, DE;
SUNDERMANN, CORINNA, DE;
HENNIES, HAGEN-HEINRICH, DE;
SCHNEIDER, JOHANNES, DE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : UTILISATION DE DERIVES SUBSTITUES D'IMIDAZO[1,2-A]PYRIDINE, D'IMIDAZO[1,2-A]PYRIMIDINE ET D'IMIDAZO[1,2-A]PYRAZINE-3-YL-AMINE DANS LA PRODUCTION DE MEDICAMENTS INHIBITEURS DE NOS

(54) Title: USE OF SUBSTITUTED IMIDAZO[1,2-A]-PYRIMIDIN-AND-PYRAZIN-3-YL-AMINE DERIVATIVES IN THE PREPARATION OF MEDICAMENTS FOR INHIBITING NOS

(57) Abrégé/Abstract:
The invention relates to the use of the compounds of the general structure (I), or the pharmaceutically acceptable salts thereof, wherein X represents CR^4 or N, Y represents CR^5 or N, and X and Y are not simultaneously N, and W represents N or NR^8. The novel compounds are used for producing a medicament for inhibiting NO synthase, for treating migraine and for treating septicemic shock, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's chorea, inflammations, inflammatory pains, cerebral ischemia, diabetes, meningitis, arteriosclerosis and/or for wound healing.

ABSTRACT

The invention relates to the use of the compounds of the general structure (I), or the pharmaceutically acceptable salts thereof, wherein X represents CR4 or N, Y represents CR5 or N, and X and Y are not simultaneously N, and W represents N or NR8. The novel compounds are used for producing a medicament for inhibiting NO synthase, for treating migraine and for treating septicemic shock, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's chorea, inflammations, inflammatory pains, cerebral ischemia, diabetes, meningitis, arteriosclerosis and/or for wound healing.

Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin- and -pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS

The invention relates to the use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin- and -pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS, in the preparation of medicaments for the treatment of migraine and in the preparation of medicaments for the treatment of septic shock, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, inflammations, inflammatory pain, cerebral ischaemia, diabetes, meningitis, arteriosclerosis and/or for healing wounds.

Nitric oxide (NO) regulates a large number of physiological processes, including neurotransmission, the relaxation and proliferation of smooth muscle, the adhesion and aggregation of thrombocytes, and also tissue damage and inflammation. Owing to the large number of signal functions, NO is associated with a number of diseases (see, for example, L.J. Ignarro, *Angew. Chem.* (1999), 111, 2002-2013 and F. Murad, *Angew. Chem. Int. Ed.* (1999), 111, 1976-1989). The enzyme responsible for the physiological formation of NO, NO synthase (NOS), plays an important part in influencing those diseases therapeutically. Hitherto, three different isoforms of NO synthase have been identified, namely the two constitutive forms nNOS and eNOS and the inducible form iNOS (see A.J. Hobbs, A. Higgs, S. Moncada, *Annu. Rev. Pharmacol. Toxicol.* (1999), *39*, 191-220; I.C. Green, P.-E. Chabrier, *DDT* (1999), 4,

47-49; P.-E. Chabrier *et al.*, *Cell. Mol. Life Sci.* (1999), 55, 1029-1035).

The inhibition of NO synthase opens up new approaches to the therapy of various diseases associated with NO (A.J. Hobbs *et al.*, *Annu. Rev. Pharmacol. Toxicol.* (1999), *39*, 191-220; I.C. Green, P.-E. Chabrier, *DDT* (1999), 4, 47-49; P.-E. Chabrier *et al.*, *Cell. Mol. Life Sci.* (1999), 55, 1029-1035), such as, for example, migraine (L.L. Thomsen, J. Olesen, *Clinical Neuroscience* (1998), *5*, 28-33; L.H. Lassen *et al.*, *The Lancet* (1997), *349*, 401-402), septic shock, neurodegenerative diseases such as multiple sclerosis, Parkinson's disease, Alzheimer's disease or Huntington's disease, inflammations, inflammatory pain, cerebral ischaemia, diabetes, meningitis and arteriosclerosis. NOS inhibition can also have an effect on the healing of wounds, on tumours and on angiogenesis, and can also effect non-specific immunity to microorganisms (A.J. Hobbs *et al.*, *Annu. Rev. Pharmacol. Toxicol.* (1999), *39*, 191-220).

NO-synthase-inhibiting active ingredients known hitherto are, in addition to L-NMMA and L-NAME - i.e. analogues of L-arginine from which NO and citrulline are formed *in vivo* with the involvement of NOS - *inter alia* S-methyl-L-citrulline, aminoguanidine, S-methylisourea, 7-nitroindazole and 2-mercaptoethylguanidine (A.J. Hobbs *et al.*, *Annu. Rev. Pharmacol. Toxicol.* (1999), *39*, 191-220).

By contrast, the object underlying the present invention was to provide novel effective NOS inhibitors.

Surprisingly, it has been found that substituted imidazo[1,2-a]-pyridin-, -pyrimidin- and -pyrazin-3-yl-amine derivatives having the general structure I



I

wherein

X represents CR^4 or N,

Y represents CR^5 or N and

X and Y do not simultaneously represent N,

W represents N or NR^8,

R^1 represents C_{1-12}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl, wherein heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, heteroaryl, wherein heteroaryl is unsubstituted or mono- or poly-substituted,

C_{1-8}-alkyl-aryl or C_{1-8}-alkyl-heteroaryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl is unsubstituted or mono- or poly-substituted and heteroaryl is unsubstituted or mono- or poly-substituted,

R^2 represents hydrogen or $C(=O)R^9$,

R^3 represents C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl, wherein heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, heteroaryl, wherein heteroaryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-C_{3-8}-cycloalkyl, C_{1-8}-alkyl-heterocyclyl, C_{1-8}-alkyl-aryl or C_{1-8}-alkyl-heteroaryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl is unsubstituted or

mono- or poly-substituted and heteroaryl is unsubstituted or mono- or poly-substituted,

R^4, R^5, R^6 and R^7 each independently of the others represents hydrogen or C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, F, Cl, Br, I, CN, NO_2, NH_2, $C(=O)R^9$, CO_2H, CO_2R^{10}, OH or OR^{11}, or

R^4 and R^5 or R^5 and R^6 or R^6 and R^7 represent a four-membered saturated or unsaturated hydrocarbon bridge having zero, 1, 2 or 3 hetero atoms selected from the group containing N, O and S, and the other radicals of R^4, R^5, R^6 and R^7 represent hydrogen,

R^8 represents $C(=O)R^9$,

R^9 represents C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl, wherein heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is

unsubstituted or mono- or poly-substituted, heteroaryl, wherein heteroaryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-aryl or C_{1-8}-alkyl-heteroaryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl is unsubstituted or mono- or poly-substituted and heteroaryl is unsubstituted or mono- or poly-substituted, and

R^{10} and R^{11} each independently of the other represents C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-aryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted and aryl is unsubstituted or mono- or poly-substituted,

are very effective NOS inhibitors.

The present invention accordingly relates to the use of the compounds having the general structure I as defined above, in the form of their bases or their pharmaceutically acceptable salts, in the preparation of a medicament for inhibiting NO synthase. The present

invention relates also to the use of a compound having the general structure I, in the form of its base or of one of its pharmaceutically acceptable salts, in the preparation of a medicament for the treatment of migraine and for the treatment of septic shock, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, inflammations, inflammatory pain, cerebral ischaemia, diabetes, meningitis, arterio-sclerosis and/or for healing wounds.

It is preferred that, of the uses according to the invention, those compounds having the general structure I in which simultaneously R^1 = tert-butyl, R^2 = H, X = CR^4 wherein R^4 = H, Y = CR^5 wherein R^5 = methyl, R^6 = H and R^7 = H or C_{1-4}-alkanyl (wherein alkanyl is straight-chain or branched and is unsubstituted or mono- or poly-substituted) are excluded.

Within the scope of this invention, the expressions "C_{1-8}-alkyl" and "C_{1-12}-alkyl" include acyclic saturated or unsaturated hydrocarbon radicals, which may be straight-chain or branched and may be unsubstituted or mono- or poly-substituted, having from 1 to 8 and from 1 to 12 carbon atoms, respectively, i.e. C_{1-8}-alkanyls, C_{2-8}-alkenyls and C_{2-8}-alkynyls, and C_{1-12}-alkanyls, C_{2-12}-alkenyls and C_{2-12}-alkynyls, where alkenyls have at least one C-C double bond and alkynyls have at least one C-C triple bond. Alkyl is advantageously selected from the group comprising methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 2-hexyl, n-octyl, 1,1,3,3-tetramethylbutyl, n-decyl, n-dodecyl; ethylenyl

(vinyl), ethynyl, propenyl ($-CH_2CH=CH_2$, $-CH=CH-CH_3$, $-C(=CH_2)-CH_3$), propynyl ($-CH-C\equiv CH$, $-C\equiv C-CH_3$), butenyl, butynyl, pentenyl, pentynyl, hexenyl, hexynyl, octenyl and octynyl.

For the purposes of this invention, the expression "C_{3-8}-cycloalkyl" means cyclic hydrocarbons having from 3 to 8 carbon atoms, which may be saturated or unsaturated, unsubstituted or mono- or poly-substituted. C_{3-8}-Cycloalkyl is advantageously selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl. Cycloalkyl is particularly preferably cyclohexyl.

The expression "heterocyclyl" denotes a 3-, 4-, 5-, 6- or 7-membered cyclic organic radical which contains at least 1, optionally also 2, 3, 4 or 5 hetero atoms, wherein the hetero atoms are identical or different and the cyclic radical is saturated or unsaturated, but is not aromatic, and may be unsubstituted or mono- or poly-substituted. The heterocycle may also be part of a bicyclic or polycyclic system. Preferred hetero atoms are nitrogen, oxygen and sulfur. It is preferred for the heterocyclyl radical to be selected from the group comprising tetrahydrofuryl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, wherein the heterocyclyl radical may be bonded to the compound having the general structure I *via* any desired ring member.

Within the scope of this invention, the expression "aryl" means aromatic hydrocarbons, *inter alia* phenyls, naphthyls and phenanthrenyls. The aryl radicals may also be condensed with other saturated, (partially) unsaturated or aromatic ring systems. Each aryl radical may be unsubstituted or mono- or poly-substituted, it being possible for the aryl substituents to be identical or different and to be at any desired possible position of the aryl. Aryl is advantageously selected from the group containing phenyl, 1-naphthyl, 2-naphthyl and phenanthren-9-yl, each of which may be unsubstituted or mono- or poly-substituted.

The expression "heteroaryl" denotes a 5-, 6- or 7-membered cyclic aromatic radical which contains at least 1, optionally also 2, 3, 4 or 5 hetero atoms, the hetero atoms being identical or different and it being possible for the heterocycle to be unsubstituted or mono- or poly-substituted; in the case of substitution on the heterocycle, the heteroaryl substituents may be identical or different and may be at any desired possible position of the heteroaryl. The heterocycle may also be part of a bicyclic or polycyclic system. Preferred hetero atoms are nitrogen, oxygen and sulfur. It is preferred for the heteroaryl radical to be selected from the group containing pyrrolyl, indolyl, furyl (furanyl), benzofuranyl, thienyl (thiophenyl), benzothienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, indolyl, indazolyl, purinyl, pyrimidinyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyl, carbazolyl, phenazinyl,

phenothiazinyl, it being possible for the heteroaryl radical to be bonded to the compounds having the general structure I *via* any desired possible ring member. Particularly preferred heteroaryl radicals for the purposes of this invention are pyridin-2-yl, pyridin-3-yl, furan-2-yl, furan-3-yl, thien-2-yl (2-thiophene), thien-3-yl (3-thiophene) and benzo[b]furan-2-yl, each of which may be unsubstituted or mono- or poly-substituted.

For the purposes of the present invention, the expressions "C_{1-8}-alkyl-C_{3-8}-cycloalkyl" and "CH_2-C_{3-8}-cycloalkyl", "C_{1-8}-alkyl-heterocyclyl", "C_{1-8}-alkyl-aryl" or "C_{1-8}-alkyl-heteroaryl" mean that C_{1-8}-alkyl (or CH_2) and cycloalkyl, heterocyclyl, aryl and heteroaryl have the meanings defined above and the cycloalkyl, heterocyclyl, aryl or heteroaryl radical is bonded to the compound having the general structure I *via* a C_{1-8}-alkyl group (or in the case of "CH_2-C_{3-8}-cycloalkyl" *via* a CH_2 group).

In connection with "alkyl", "alkanyl", "alkenyl" and "alkynyl", the term "substituted" within the scope of this invention is understood to mean the substitution of a hydrogen radical by F, Cl, Br, I, -CN, -N≡C, NH_2, NH-alkyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH-heterocyclyl, NH-alkyl-OH, $N(alkyl)_2$, $N(alkyl\text{-}aryl)_2$, $N(alkyl\text{-}heteroaryl)_2$, $N(heterocyclyl)_2$, $N(alkyl\text{-}OH)_2$, NO, NO_2, SH, S-alkyl, S-aryl, S-heteroaryl, S-alkyl-aryl, S-alkyl-heteroaryl, S-heterocyclyl, S-alkyl-OH, S-alkyl-SH, OH, O-alkyl, O-aryl, O-heteroaryl, O-alkyl-aryl, O-alkyl-heteroaryl, O-heterocyclyl, O-alkyl-OH, CHO, $C(=O)C_{1-6}$-alkyl, $C(=S)C_{1-6}$-alkyl,

$C(=O)$aryl, $C(=S)$aryl, $C(=O)C_{1-6}$-alkyl-aryl,



wherein n = 1, 2 or 3, $C(=S)C_{1-6}$-alkyl-aryl, C(=O)-heteroaryl, C(=S)-heteroaryl, C(=O)-heterocyclyl, C(=S)-heterocyclyl, CO_2H, CO_2-alkyl, CO_2-alkyl-aryl, $C(=O)NH_2$, C(=O)NH-alkyl, C(=O)NH-aryl, C(=O)NH-heterocyclyl, $C(=O)N(alkyl)_2$, $C(=O)N(alkyl\text{-}aryl)_2$, $C(=O)N(alkyl\text{-}heteroaryl)_2$, $C(=O)N(heterocyclyl)_2$, SO-alkyl, SO_2-alkyl, SO_2NH_2, SO_3H, $PO(O\text{-}C_{1-6}\text{-}alkyl)_2$, $Si(C_{1-6}\text{-}alkyl)_3$, $Si(C_{3-8}\text{-}cycloalkyl)_3$, $Si(CH_2\text{-}C_{3-8}\text{-}cycloalkyl)_3$, $Si(phenyl)_3$, cycloalkyl, aryl, heteroaryl or by heterocyclyl, where polysubstituted radicals are understood to be radicals that are polysubstituted, for example di- or tri-substituted, either on different atoms or on the same atoms, for example trisubstituted on the same carbon atom, as in the case of CF_3 or $-CH_2CF_3$, or at different positions, as in the case of $-CH(OH)-CH=CH-CHCl_2$. Polysubstitution can be carried out with the same or with different substituents. It is also possible for a substituent itself to be substituted; accordingly, -Oalkyl also includes, *inter alia*, $-O-CH_2-CH_2-O-CH_2-CH_2-OH$. For the purposes of the present invention, "alkyl" in this context particularly preferably means methyl, ethyl, CH_2-OH, CH_2CO_2H, CH_2CO_2methyl, $CH_2PO(O\text{-}C_{1-6}\text{-}alkanyl)_2$, $CH_2Si(C_{1-6}\text{-}alkanyl)_3$, $CH_2Si(C_{3-8}\text{-}cycloalkyl)_3$, $CH_2Si(CH_2\text{-}C_{3-8}\text{-}cycloalkyl)_3$, $CH_2Si(phenyl)_3$, CH_2CH_2-morpholin-4-yl, CH_2-aryl, CF_3 or $(CH_2)_n$-N≡C wherein n = 2, 3, 4, 5 or, especially, 6.

In relation to "aryl", "heterocyclyl", "heteroaryl" and "cycloalkyl", "mono- or poly-substituted" within the scope of this invention is understood to mean the mono- or poly-substitution, for example di-, tri- or tetra-substitution, of one or more hydrogen atoms of the ring system by F, Cl, Br, I, CN, NH_2, NH-alkyl, NH-aryl, NH-heteroaryl, NH-alkyl-aryl, NH-alkyl-heteroaryl, NH-heterocyclyl, NH-alkyl-OH, $N(alkyl)_2$, $N(alkyl\text{-}aryl)_2$, $N(alkyl\text{-}heteroaryl)_2$, $N(heterocyclyl)_2$, $N(alkyl\text{-}OH)_2$, NO, NO_2, SH, S-alkyl, S-cycloalkyl, S-aryl, S-heteroaryl, S-alkyl-aryl, S-alkyl-heteroaryl, S-heterocyclyl, S-alkyl-OH, S-alkyl-SH, OH, O-alkyl, O-cycloalkyl, O-aryl, O-heteroaryl, O-alkyl-aryl, O-alkyl-heteroaryl, O-heterocyclyl, O-alkyl-OH, CHO, $C(=O)C_{1\text{-}6}$-alkyl, $C(=S)C_{1\text{-}6}$-alkyl, C(=O)aryl, C(=S)aryl, $C(=O)C_{1\text{-}6}$-alkyl-aryl,



wherein n = 1, 2 or 3, $C(=S)C_{1\text{-}6}$-alkyl-aryl, C(=O)-heteroaryl, C(=S)-heteroaryl, C(=O)-heterocyclyl, C(=S)-heterocyclyl, CO_2H, CO_2-alkyl, CO_2-alkyl-aryl, $C(=O)NH_2$, C(=O)NH-alkyl, C(=O)NH-aryl, C(=O)NH-heterocyclyl, $C(=O)N(alkyl)_2$, $C(=O)N(alkyl\text{-}aryl)_2$, $C(=O)N(alkyl\text{-}heteroaryl)_2$, $C(=O)N(heterocyclyl)_2$, S(O)-alkyl, S(O)-aryl, SO_2-alkyl, SO_2-aryl, SO_2NH_2, SO_3H, CF_3, =O, =S; alkyl, cycloalkyl, aryl, heteroaryl and/or by heterocyclyl; on one or, optionally, different atoms (it being possible for a substituent itself to be substituted). Polysubstitution is carried out with the same or with different substituents. Particularly preferred substituents for "aryl" are -F, -Cl, -Br, $-CF_3$, -OH, $-O\text{-}CH_3$, $-O\text{-}CH_2CH_3$, methyl, n-propyl, carboxy ($-CO_2H$), nitro, 4-chlorophenoxy, acetoxy and dimethylamino.

Particularly preferred substituents for "heteroaryl" are methyl-OH, -O-CH_3, -CH_2OH, -NO_2, -CO_2H, -CO_2ethyl, acetoxymethyl, -Br, -Cl, -methylsulfanyl (-S-CH_3), nitrophenyl, chlorophenyl and -[1,3]-dioxolan. Particularly preferred substituents for "cycloalkyl" are CO_2H and CO_2ethyl. Preferred substituents for "heterocyclyl" are methyl and ethyl.

Pharmaceutically acceptable salts within the scope of this invention are those salts of the compounds according to the invention having the general structure I which, when used pharmaceutically, are physiologically tolerable - especially when administered to mammals and/or humans. Such pharmaceutically acceptable salts can be formed, for example, with inorganic or organic acids.

The pharmaceutically acceptable salts of the compounds according to the invention having the general structure I are preferably formed with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid or aspartic acid. The salts that are formed are, *inter alia*, hydrochlorides, hydrobromides, phosphates, carbonates, hydrogen carbonates, formates, acetates, oxalates, succinates, tartrates, fumarates, citrates and glutamates. Also preferred are solvates and, especially, the hydrates of the compounds according to the invention, which can be

obtained, for example, by crystallisation from aqueous solution.

If the compounds having the general structure I have at least one centre of asymmetry, they may be in the form of their racemates, in the form of the pure enantiomers and/or diastereoisomers or in the form of mixtures of those enantiomers or diastereoisomers, both in substance and in the form of pharmaceutically acceptable salts of those compounds. The mixtures can be present in any desired mixing ratio of the stereoisomers. Chiral compounds having the general structure I are preferably in the form of enantiomerically pure compounds.

For the preparation according to the invention of a medicament for inhibiting NOS, for the treatment of migraine or for the treatment of septic shock, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, inflammations, inflammatory pain, cerebral ischaemia, diabetes, meningitis, arterio-sclerosis and/or for healing wounds, it is preferred to use those compounds having the general structure I (in the form of their bases or of their pharmaceutically acceptable salts) in which

R^1 represents methyl, ethyl, n-propyl, 2-propyl, n-butyl, tert-butyl, n-hexyl, n-octyl, 1,1,3,3-tetramethyl-butyl, CH_2aryl, wherein aryl is unsubstituted or mono- or poly-substituted, CH_2CO_2-C_{1-6}-alkyl, wherein alkyl is straight-chain or branched, $CH_2PO(O\text{-}C_{1-6}\text{-alkyl})_2$, wherein alkyl is straight-chain or branched, $CH_2SiR^{12}R^{13}R^{14}$, CH_2CH_2-morpholin-4-yl, $(CH_2)_n$-NC, wherein n = 2, 3, 4, 5 or 6, C_{3-8}-cycloalkyl, wherein cyclo-

alkyl is unsubstituted or mono- or poly-substituted, or phenyl, wherein phenyl is unsubstituted or mono- or poly-substituted,

R^2 represents H or C(=O)-C_{1-4}-alkyl,

R^3 represents methyl, ethyl, n-propyl, 2-propyl, n-butyl, tert-butyl, cyclopropyl, cyclopentyl or cyclohexyl, which are unsubstituted or mono- or poly-substituted, phenyl, wherein phenyl is unsubstituted or mono- or poly-substituted, 1-naphthyl or 2-naphthyl, wherein naphthyl is unsubstituted or mono- or poly-substituted, 9-phenanthrenyl, pyrrol-2-yl, pyrrol-3-yl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, wherein pyrrolyl or pyridinyl are unsubstituted or mono- or poly-substituted, furan-2-yl or furan-3-yl, wherein furanyl is unsubstituted or mono- or poly-substituted, thien-2-yl or thien-3-yl, wherein thienyl is unsubstituted or mono- or poly-substituted, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, wherein imidazolyl is unsubstituted or mono- or poly-substituted, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, wherein thiazolyl is unsubstituted or mono- or poly-substituted, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, wherein oxazolyl is unsubstituted or mono- or poly-substituted, isooxazol-3-yl, isooxazol-4-yl, isooxazol-5-yl, wherein isooxazolyl is unsubstituted or mono- or poly-substituted, indol-2-yl, benzofuran-2-yl or benzofuran-3-yl,

R^4, R^5, R^6 and R^7 each independently of the others represents H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, tert-butyl, CF_3, F, Cl, Br, I, CO_2H, CO_2methyl, CO_2ethyl, $C(=O)CH_3$ or NO_2, or R^6 and R^7 form the hydrocarbon bridge -CH=CH-CH=CH-,

R^8 represents $C(=O)CH_3$ and

R^{12}, R^{13} and R^{14} each independently of the others represents C_{1-6}-alkyl, wherein alkyl is straight-chain or branched and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is unsubstituted or mono- or poly-substituted, or phenyl, wherein phenyl is unsubstituted or mono- or poly-substituted.

Further preference is given to the use according to the invention of compounds having the general structure I in which

R^1 represents methyl, ethyl, n-propyl, 2-propyl, n-butyl, tert-butyl, n-hexyl, n-octyl, 1,1,3,3-tetramethyl-butyl, CH_2aryl, wherein aryl is unsubstituted or mono- or poly-substituted, CH_2CO_2-C_{1-6}-alkyl, wherein alkyl is straight-chain or branched, $CH_2PO(O\text{-}C_{1-6}\text{-alkyl})_2$, wherein alkyl is straight-chain or branched, $CH_2SiR^{12}R^{13}R^{14}$, CH_2CH_2-morpholin-4-yl, $(CH_2)_n$-NC, wherein n = 2, 3, 4, 5 or 6, C_{3-8}-cycloalkyl, wherein cycloalkyl is unsubstituted or mono- or poly-substituted, or phenyl, wherein phenyl is unsubstituted or mono- or poly-substituted,

R^2 represents H or $C(=O)$-C_{1-4}-alkyl,

R^3 represents methyl, ethyl, n-propyl, 2-propyl, n-butyl, tert-butyl, cyclopropyl, cyclopentyl or cyclohexyl, which, independently of one another, are unsubstituted or mono- or poly-substituted, phenyl, wherein phenyl is unsubstituted or monosubstituted or polysubstituted by identical or different substituents selected from methyl, ethyl, n-propyl, prop-2-yl, n-butyl, sec-butyl, tert-butyl, isobutyl,

CF_3, OH, Omethyl, Oethyl, F, Cl, Br, I, CN, NO_2, 4-chlorophenoxy, acetoxy and dimethylamino; 1-naphthyl or 2-naphthyl, wherein naphthyl is unsubstituted or monosubstituted or polysubstituted by identical or different substituents selected from methyl, ethyl, n-propyl, prop-2-yl, n-butyl, sec-butyl, tert-butyl, isobutyl, CF_3, OH, Omethyl, Oethyl, F, Cl, Br, I, CN, NO_2, 4-chlorophenoxy, acetoxy and dimethylamino; 9-phenanthrenyl, pyrrol-2-yl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, wherein pyridinyl is unsubstituted or monosubstituted or polysubstituted by identical or different substituents selected from methyl, ethyl, n-propyl, prop-2-yl, n-butyl, sec-butyl, tert-butyl, isobutyl, CF_3, OH, Omethyl, Oethyl, F, Cl, Br, I, CN, NO_2, 4-chlorophenoxy, acetoxy, dimethylamino, carboxy, carboxymethyl, carboxyethyl, hydroxymethyl, chlorophenyl, nitrophenyl, [1,3]-dioxolan and methylsulfanyl; furan-2-yl or furan-3-yl, wherein furanyl is unsubstituted or monosubstituted or polysubstituted by identical or different substituents selected from methyl, ethyl, n-propyl, prop-2-yl, n-butyl, sec-butyl, tert-butyl, isobutyl, CF_3, OH, Omethyl, Oethyl, F, Cl, Br, I, CN, NO_2, 4-chlorophenoxy, acetoxy, dimethylamino, carboxy, carboxymethyl, carboxyethyl, hydroxymethyl, chloro-phenyl, nitrophenyl, [1,3]-dioxolan and methyl-sulfanyl; thien-2-yl or thien-3-yl, wherein thienyl is unsubstituted or monosubstituted or polysubstituted by identical or different substituents selected from methyl, ethyl, n-propyl, prop-2-yl, n-butyl, sec-butyl, tert-butyl, isobutyl, CF_3, OH, Omethyl, Oethyl, F, Cl, Br, I, CN, NO_2, 4-

chlorophenoxy, acetoxy, dimethylamino, carboxy, carboxymethyl, carboxyethyl, hydroxymethyl, chlorophenyl, nitrophenyl, [1,3]-dioxolan and methylsulfanyl; indol-2-yl, benzofuran-2-yl or benzofuran-3-yl,

R^4, R^5, R^6 and R^7 each independently of the others represents H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, tert-butyl, CF_3, F, Cl, Br, I, CO_2H, CO_2methyl, CO_2ethyl, $C(=O)CH_3$ or NO_2, or R^6 and R^7 form the hydrocarbon bridge $-CH=CH-CH=CH-$,

R^8 represents $C(=O)CH_3$ and

R^{12}, R^{13} and R^{14} each independently of the others represents C_{1-6}-alkyl, wherein alkyl is straight-chain or branched and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is unsubstituted or mono- or poly-substituted, or phenyl, wherein phenyl is unsubstituted or mono- or poly-substituted.

Particular preference is given to the use according to the invention of compounds having the general structure I in which

R^1 represents methyl, n-butyl, 1,1,3,3-tetramethylbutyl, benzyl, 2-chlorobenzyl, 2-methoxybenzyl, $CH_2CO_2CH_3$, $(CH_2)_6$-NC, cyclopentyl, cyclohexyl, phenyl, 2,6-dimethylphenyl, 3-chlorophenyl or 3-chloro-4-fluorophenyl,

R^2 represents H or $C(=O)CH_3$,

R^3 represents methyl, tert-butyl, cyclohexyl, phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-hydroxyphenyl, 2-methoxyphenyl,

3-hydroxyphenyl, 3-methoxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-(4-chlorophenoxy)-phenyl, 2,4-dimethylphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3-methoxy-4-acetoxyphenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2-chloro-4-fluorophenyl, 2-chloro-6-fluorophenyl, 4-bromo-2-fluorophenyl, 3,4,5-trimethoxyphenyl, 1-naphthyl, 2-ethoxy-naphth-1-yl, 4-dimethylamino-napth-1-yl, 9-phenanthrenyl, pyrrol-2-yl, N-methylpyrrol-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, furan-2-yl, furan-3-yl, 5-methyl-furan-2-yl, 4,5-dimethyl-furan-2-yl, 5-hydroxymethyl-furan-2-yl, 5-acetoxymethyl-furan-2-yl, 5-carboxy-furan-2-yl, 5-[1,3]-dioxolan-furan-2-yl, 3-bromo-furan-2-yl, 5-bromo-furan-2-yl, 5-nitro-furan-2-yl, 5-(2-nitrophenyl)-furan-2-yl, 5-(2-chlorophenyl)-furan-2-yl, 5-(3-chlorophenyl)-furan-2-yl, 5-(3-chlorophenyl)-furan-3-yl, 5-(4-chlorophenyl)-furan-2-yl, benzo[b]furan-2-yl, thien-2-yl, thien-3-yl, 5-methyl-thien-2-yl, 5-carboxy-thien-2-yl, 3-bromo-thien-2-yl, 5-chloro-thien-2-yl or 5-methyl-sulfanyl-thien-2-yl,

R^4 represents H, CH_3, Cl, Br or CO_2H,

R^5 represents H, CH_3, C_2H_5 or Cl,

R^6 represents H, CH_3, Cl, Br or NO_2,

R^7 represents H, CH_3 or n-C_3H_7 and

R^8 represents $C(=O)CH_3$.

Very particular preference is given to the use of compounds in which R^4 and R^6 represent H, R^5 represents H, CH_3 or C_2H_5 and R^7 represents H or CH_3.

The compounds having the general structure I (in the form of their bases or of their pharmaceutically acceptable salts), which are to be used for the preparation according to the invention of a medicament for inhibiting NOS, for the treatment of migraine or for the treatment of septic shock, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, inflammations, inflammatory pain, cerebral ischaemia, diabetes, meningitis, arteriosclerosis and/or for healing wounds, are preferably selected from the group containing:

tert-butyl-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,

cyclohexyl-(5,7-dimethyl-2-pyridin-4-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,

(5,7-dimethyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,

{6-[5,7-dimethyl-2-(1H-pyrrol-2-yl)-imidazo[1,2-a]-pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,

tert-butyl-[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-amine,

[2-(3,4-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,

cyclohexyl-(7-methyl-2-pyridin-4-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,

(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,

(1,1,3,3-tetramethyl-butyl)-(2,5,7-trimethyl-imidazo-[1,2-a]pyridin-3-yl)-amine,
cyclohexyl-(7-methyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-amine,
cyclohexyl-(7-methyl-2-thiophen-2-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
(5,7-dimethyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
cyclohexyl-[7-methyl-2-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyridin-3-yl]-amine,
tert-butyl-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-amine,
(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
cyclohexyl-(7-methyl-2-naphthalen-1-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
[2-(2-fluoro-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
(2,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino)-acetic acid methyl ester,
methylidyne-[6-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-ylamino)-hexyl]-ammonium,
3-(3-tert-butylamino-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl)-phenol,
cyclohexyl-[2-(2-fluoro-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-amine,
tert-butyl-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine,
cyclohexyl-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
3-(3-tert-butylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenol,

tert-butyl-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine,
cyclohexyl-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine,
cyclohexyl-(5,7-dimethyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
(2-furan-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
(7-methyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
butyl-(2-cyclohexyl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-amine,
3-[5,7-dimethyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo[1,2-a]pyridin-2-yl]-phenol,
(2,6-dimethyl-phenyl)-(5,7-dimethyl-2-o-tolyl-imidazo-[1,2-a]pyridin-3-yl)-amine,
tert-butyl-(7-methyl-2-naphthalen-1-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
(2,6-dimethyl-phenyl)-[2-(2-fluoro-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-amine,
cyclohexyl-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-amine,
[5,7-dimethyl-2-(1H-pyrrol-2-yl)-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
butyl-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amine,
(5,7-dimethyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
[2-(2,3-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,
(2,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,

[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-7-methyl-imidazo-[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
[2-(3-bromo-thiophen-2-yl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,
(2,6-dimethyl-phenyl)-[2-(2-fluoro-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amine,
(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
[6-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-methylidyne-ammonium,
(7-methyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
[2-(2,3-dichloro-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,
[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,
butyl-[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-amine,
methylidyne-[6-(7-methyl-2-p-tolyl-imidazo[1,2-a]-pyridin-3-ylamino)-hexyl]-ammonium,
tert-butyl-[5,7-dimethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-amine,
acetic acid 5-(3-cyclohexylamino-5,7-dimethyl-imidazo-[1,2-a]pyridin-2-yl)-furan-2-yl methyl ester,
[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
[2-(3,4-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,
3-(3-butylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenol,
(2-benzofuran-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,

(2-benzofuran-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(2,6-dimethyl-phenyl)-amine,
acetic acid 5-(3-cyclohexylamino-7-methyl-imidazo-[1,2-a]pyridin-2-yl)-furan-2-yl methyl ester,
[6-(5,7-dimethyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-methylidyne-ammonium,
butyl-[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-amine,
{6-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,
{5-[5,7-dimethyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo[1,2-a]pyridin-2-yl]-furan-2-yl}-methanol,
(7-methyl-2-naphthalen-1-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
[5-(3-tert-butylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-yl]-methanol,
tert-butyl-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amine,
(2-benzofuran-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
5-(3-tert-butylamino-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-carboxylic acid,
tert-butyl-(2-furan-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-amine,
cyclohexyl-(2,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amine,
[2-(2,3-dichlorophenyl)-8-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
(7-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
(2,6-dimethyl-phenyl)-[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amine,

3-(3-butylamino-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl)-phenol,

butyl-[2-(2,3-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-amine,

{6-[5,7-dimethyl-2-(2-trifluoromethyl-phenyl)-imidazo-[1,2-a]pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,

tert-butyl-(7-methyl-2-pyridin-2-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,

cyclohexyl-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine,

[2-(2,3-dichlorophenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,

(2,6-dimethyl-phenyl)-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-amine,

{2-[5-(2-chlorophenyl)-furan-2-yl]-7-methyl-imidazo[1,2-a]pyridin-3-yl}-(1,1,3,3-tetramethyl-butyl)-amine,

5-[7-methyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo-[1,2-a]pyridin-2-yl]-furan-2-carboxylic acid,

cyclohexyl-[2-(2-methoxy-phenyl)-8-methyl-imidazo-[1,2-a]pyridin-3-yl]-amine,

3-[7-methyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo-[1,2-a]pyridin-2-yl]-phenol,

[2-(2,3-dichlorophenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,

[2-(2,4-dichlorophenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,

[2-(5-bromofuran-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,

5-(3-cyclohexylamino-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-carboxylic acid,

[6-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-methylidyne-ammonium,
[2-(2,4-dichlorophenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
(2-benzofuran-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-(2,6-dimethyl-phenyl)-amine,
5-(3-cyclohexylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-carboxylic acid,
{6-[2-(2-bromophenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,
tert-butyl-(2-cyclohexyl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-amine,
tert-butyl-(2,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amine,
(5,7-dimethyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
[2-(2,3-dichlorophenyl)-8-methyl-imidazo[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,
methylidyne-[6-(7-methyl-2-o-tolyl-imidazo[1,2-a]-pyridin-3-ylamino)-hexyl]-ammonium,
{2-[5-(3-chlorophenyl)-furan-2-yl]-7-methyl-imidazo-[1,2-a]pyridin-3-yl}-(1,1,3,3-tetramethyl-butyl)-amine,
cyclohexyl-[7-methyl-2-(5-nitro-furan-2-yl)-imidazo-[1,2-a]pyridin-3-yl]-amine,
[2-(2-bromophenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-cyclohexyl-amine,
[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
{5-[7-methyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo[1,2-a]pyridin-2-yl]-furan-2-yl}-methanol,
(6-{2-[5-(2-chlorophenyl)-furan-2-yl]-5-methyl-imidazo-[1,2-a]pyridin-3-ylamino}-hexyl)-methylidyne-ammonium,

cyclohexyl-[5,7-dimethyl-2-(5-nitro-furan-2-yl)-imidazo-[1,2-a]pyridin-3-yl]-amine,
cyclohexyl-[2-(4,5-dimethyl-furan-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amine,
[6-(5,7-dimethyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-methylidyne-ammonium,
methylidyne-[6-(7-methyl-2-pyridin-2-yl-imidazo[1,2-a]-pyridin-3-ylamino)-hexyl]-ammonium,
[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
{6-[2-(3,4-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,
5-(3-tert-butylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-thiophene-2-carboxylic acid,
cyclohexyl-(8-methyl-2-pyridin-4-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
[2-(2,3-dichloro-phenyl)-6-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
5-(3-butylamino-imidazo[1,2-a]pyrazin-2-yl)-thiophene-2-carboxylic acid,
cyclohexyl-(5,7-dimethyl-2-pyridin-2-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
(2-benzofuran-2-yl-8-methyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
{6-[2-(2-fluoro-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,
[2-(2,3-dimethoxy-phenyl)-8-methyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
methylidyne-[6-(7-methyl-2-phenanthren-9-yl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-ammonium,
5-(3-tert-butylamino-imidazo[1,2-a]pyrazin-2-yl)-thiophene-2-carboxylic acid,

tert-butyl-(8-methyl-2-pyridin-2-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
cyclohexyl-(2-furan-2-yl-8-methyl-imidazo[1,2-a]pyridin-3-yl)-amine,
methylidyne-[6-(7-methyl-2-naphthalen-1-yl-imidazo-[1,2-a]pyridin-3-ylamino)-hexyl]-ammonium,
tert-butyl-(2-cyclohexyl-8-methyl-imidazo[1,2-a]pyridin-3-yl)-amine,
(6-methyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
tert-butyl-(6-methyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyrimidin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
5-(3-tert-butylamino-6-methyl-imidazo[1,2-a]pyridin-2-yl)-thiophene-2-carboxylic acid,
[6-(5,7-dimethyl-2-naphthalen-1-yl-imidazo[1,2-a]-pyridin-3-ylamino)-hexyl]-methylidyne-ammonium,
3-[3-(2,6-dimethyl-phenylamino)-5,7-dimethyl-imidazo-[1,2-a]pyridin-2-yl]-phenol,
(2,6-dimethyl-phenyl)-(8-methyl-2-o-tolyl-imidazo-[1,2-a]pyridin-3-yl)-amine,
{6-[2-(3-hydroxy-phenyl)-8-methyl-imidazo[1,2-a]pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,
{5-[3-(2,6-dimethyl-phenylamino)-7-methyl-imidazo-[1,2-a]pyrimidin-2-yl]-furan-2-yl}-methanol,
(8-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
[2-(2,4-dichlorophenyl)-6-methyl-imidazo[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,
butyl-[2-(2,4-dichloro-phenyl)-6-methyl-imidazo[1,2-a]-pyridin-3-yl]-amine,

butyl-[2-(4-dimethylamino-naphthalen-1-yl)-imidazo-[1,2-a]pyrazin-3-yl]-amine,

{6-[2-(2-bromo-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,

butyl-[2-(2-methoxy-phenyl)-6-methyl-imidazo[1,2-a]-pyridin-3-yl]-amine,

(2-cyclohexyl-8-methyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,

cyclohexyl-(7-methyl-2-pyridin-2-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,

cyclohexyl-(2-furan-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-amine,

(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino)-acetic acid methyl ester,

N-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-tert-butyl-N-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,

N-tert-butyl-N-(2-furan-2-yl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

N-(5,7-dimethyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-(5,7-dimethyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-(2,6-dimethyl-phenyl)-N-(5,7-dimethyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-acetamide,

N-(2-furan-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-(1,1,3,3-tetramethyl-butyl)-N-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-acetamide,

N-cyclohexyl-N-(7-methyl-2-thiophen-2-yl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,

N-tert-butyl-N-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-acetamide,

5-[3-(acetyl-tert-butyl-amino)-imidazo[1,2-a]pyrazin-2-yl]-thiophene-2-carboxylic acid,

5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl}-furan-2-carboxylic acid,

N-[2-(5-hydroxymethyl-furan-2-yl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-[2-(3-bromo-thiophen-2-yl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide,

N-tert-butyl-N-(2-cyclohexyl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

acetic acid 5-[3-(acetyl-cyclohexyl-amino)-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl]-furan-2-yl methyl ester,

{6-[acetyl-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium,

N-[2-(2,3-dichloro-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide,

N-[2-(3-bromo-thiophen-2-yl)-imidazo[1,2-a]pyridin-3-yl]-N-cyclohexyl-acetamide,

N-(5,7-dimethyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-cyclohexyl-N-(7-methyl-2-pyridin-4-yl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,

N-cyclohexyl-N-[7-methyl-2-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetamide,

N-(6,8-dibromo-2-furan-2-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-(7-methyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

acetic acid 5-[3-(acetyl-cyclohexyl-amino)-7-methyl-imidazo[1,2-a]pyridin-2-yl]-furan-2-yl methyl ester,
N-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-[2-(2,3-dichloro-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide,
N-cyclohexyl-N-[5,7-dimethyl-2-(5-methyl-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-butyl-N-[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-cyclohexyl-N-[5,7-dimethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-acetamide,
[acetyl-(2,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amino]-acetic acid methyl ester,
N-cyclohexyl-N-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-acetamide,
5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-imidazo[1,2-a]pyridin-2-yl}-thiophene-2-carboxylic acid,
N-[2-(2,4-dichloro-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-cyclohexyl-N-[7-methyl-2-(5-nitro-furan-2-yl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide,
N-(2-tert-butyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-acetamide,
N-(2,6-dimethyl-phenyl)-N-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-[2-(3-hydroxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-(2,6-dimethyl-phenyl)-N-[2-(2-fluoro-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,

5-[3-(acetyl-tert-butyl-amino)-5-methyl-imidazo[1,2-a]-pyridin-2-yl]-thiophene-2-carboxylic acid,
N-(2,6-dimethyl-phenyl)-N-[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-(7-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-7-methyl-imidazo[1,2-a]pyridin-2-yl}-furan-2-carboxylic acid,
N-cyclohexyl-N-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,
N-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-(2-benzofuran-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-acetamide,
N-tert-butyl-N-(2-furan-2-yl-7-methyl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,
N-tert-butyl-N-(7-methyl-2-pyridin-2-yl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,
N-cyclohexyl-N-(5,7-dimethyl-2-pyridin-3-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,
N-[2-(2,3-dichloro-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-{2-[3-(4-chloro-phenoxy)-phenyl]-imidazo[1,2-a]-pyridin-3-yl}-N-(2,6-dimethyl-phenyl)-acetamide,
N-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

5-[3-(acetyl-cyclohexyl-amino)-5,7-dimethyl-imidazo-[1,2-a]pyridin-2-yl]-furan-2-carboxylic acid,

N-tert-butyl-N-[7-methyl-2-(5-nitro-furan-2-yl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide,

N-[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-[2-(5-methyl-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

5-[3-(acetyl-tert-butyl-amino)-7-methyl-imidazo[1,2-a]-pyridin-2-yl]-furan-2-carboxylic acid,

N-[2-(4,5-dimethyl-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-cyclohexyl-N-(2-furan-2-yl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

N-tert-butyl-N-(7-methyl-2-naphthalen-1-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-imidazo-[1,2-a]pyrazin-2-yl}-thiophene-2-carboxylic acid,

N-butyl-N-(2-o-tolyl-imidazo[1,2-a]pyrimidin-3-yl)-acetamide,

N-[2-(3,4-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide,

N-tert-butyl-N-(7-methyl-2-phenanthren-9-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

N-(2,6-dimethyl-phenyl)-N-[2-(2-fluoro-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,

N-[2-(2-methoxy-phenyl)-8-methyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-(2,6-dimethyl-phenyl)-N-[2-(3-hydroxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,

N-(2-tert-butyl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-acetamide,

acetic acid 4-{3-[acetyl-(2,6-dimethyl-phenyl)-amino]-6-bromo-8-methyl-imidazo[1,2-a]pyridin-2-yl}-2-methoxy-phenyl ester,

N-tert-butyl-N-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,

[6-(acetyl-{7-methyl-2-[5-(2-nitro-phenyl)-furan-2-yl]-imidazo[1,2-a]pyridin-3-yl}-amino)-hexyl]-methylidyne-ammonium,

N-(2-benzofuran-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-(2-benzofuran-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

5-[3-(acetyl-tert-butyl-amino)-imidazo[1,2-a]pyridin-2-yl]-thiophene-2-carboxylic acid,

N-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-tert-butyl-N-[2-(5-methyl-furan-2-yl)-imidazo[1,2-a]-pyridin-3-yl]-acetamide,

N-tert-butyl-N-[2-(5-methylsulfanyl-thiophen-2-yl)-imidazo[1,2-a]pyrimidin-3-yl]-acetamide,

N-[2-(4,5-dimethyl-furan-2-yl)-5-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-butyl-N-[2-(2,4-dichloro-phenyl)-imidazo[1,2-a]-pyrimidin-3-yl]-acetamide,

N-[2-(3-bromo-thiophen-2-yl)-6-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-cyclohexyl-acetamide,

5-{3-[acetyl-(2,6-dimethyl-phenyl)-amino]-6-methyl-imidazo[1,2-a]pyridin-2-yl}-thiophene-2-carboxylic acid,

N-butyl-N-[2-(2,3-dimethoxy-phenyl)-7-methyl-imidazo-[1,2-a]pyridin-3-yl]-acetamide,

N-tert-butyl-N-[2-(2,3-dichloro-phenyl)-imidazo[1,2-a]-pyridin-3-yl]-acetamide,

N-(2-furan-2-yl-5-propyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

5-[3-(acetyl-cyclohexyl-amino)-imidazo[1,2-a]pyridin-2-yl]-thiophene-2-carboxylic acid,

5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-8-methyl-imidazo[1,2-a]pyridin-2-yl}-furan-2-carboxylic acid,

3-(acetyl-butyl-amino)-2-pyridin-2-yl-imidazo[1,2-a]-pyridine-8-carboxylic acid,

{6-[acetyl-(5,7-dimethyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium,

N-tert-butyl-N-[2-(5-methylsulfanyl-thiophen-2-yl)-imidazo[1,2-a]pyrazin-3-yl]-acetamide,

5-[3-(acetyl-cyclohexyl-amino)-5-methyl-imidazo[1,2-a]-pyridin-2-yl]-thiophene-2-carboxylic acid,

N-[2-(5-methylsulfanyl-thiophen-2-yl)-imidazo[1,2-a]-pyrazin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-[2-(2,3-dichloro-phenyl)-5-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide,

N-butyl-N-[2-(2-methoxy-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetamide,

(6-{acetyl-[2-(2-methoxy-phenyl)-6-nitro-imidazo[1,2-a]-pyridin-3-yl]-amino}-hexyl)-methylidyne-ammonium,

N-(2-benzofuran-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-acetamide,

(6-{acetyl-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-amino}-hexyl)-methylidyne-ammonium,

{6-[acetyl-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium,

N-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

acetic acid 5-{3-[acetyl-(2,6-dimethyl-phenyl)-amino]-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl}-furan-2-yl methyl ester,

{acetyl-[2-(3-hydroxy-phenyl)-6-methyl-imidazo[1,2-a]-pyridin-3-yl]-amino}-acetic acid methyl ester,

N-tert-butyl-N-[2-(2-trifluoromethyl-phenyl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide,

N-butyl-N-[2-(2-chloro-4-fluoro-phenyl)-imidazo[1,2-a]-pyridin-3-yl]-acetamide,

N-[2-(2,4-dichloro-phenyl)-imidazo[1,2-a]pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide,

5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-7-methyl-imidazo[1,2-a]pyrimidin-2-yl}-furan-2-carboxylic acid,

acetic acid 5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-imidazo[1,2-a]pyrimidin-2-yl}-furan-2-yl methyl ester,

N-(2,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

acetic acid 4-[3-(acetyl-cyclohexyl-amino)-5-amino-7-chloro-imidazo[1,2-a]pyrimidin-2-yl]-2-methoxy-phenyl ester,

acetic acid 4-[3-(acetyl-cyclohexyl-amino)-5,7-dimethyl-imidazo[1,2-a]pyrimidin-2-yl]-2-methoxy-phenyl ester,

N-[6-bromo-2-(2-chloro-6-fluoro-phenyl)-8-methyl-imidazo[1,2-a]pyridin-3-yl]-N-cyclohexyl-acetamide,

N-[2-(2-chloro-6-fluoro-phenyl)-5-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-cyclohexyl-acetamide,

N-butyl-N-[2-(2,3-dichloro-phenyl)-imidazo[1,2-a]-pyrimidin-3-yl]-acetamide,

N-[2-(5-chloro-thiophen-2-yl)-imidazo[1,2-a]pyrimidin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

[acetyl-(2-cyclohexyl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-amino]-acetic acid methyl ester,
N-tert-butyl-N-[2-(2-chloro-6-fluoro-phenyl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide,
N-cyclohexyl-N-(5,7-dimethyl-2-pyridin-2-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,
acetic acid 5-[3-(acetyl-cyclohexyl-amino)-5-methyl-imidazo[1,2-a]pyridin-2-yl]-furan-2-yl methyl ester,
N-(2,6-dimethyl-phenyl)-N-[6-methyl-2-(2-trifluoro-methyl-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-cyclohexyl-N-(2-furan-2-yl-7-methyl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,
N-cyclohexyl-N-(7-methyl-2-pyridin-2-yl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,
N-cyclohexyl-N-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-5-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-tert-butyl-N-(5-propyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,
N-tert-butyl-N-[2-(5-methyl-thiophen-2-yl)-imidazo-[1,2-a]pyrimidin-3-yl]-acetamide,
3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-2-furan-2-yl-imidazo[1,2-a]pyridine-8-carboxylic acid,
N-tert-butyl-N-[2-(4,5-dimethyl-furan-2-yl)-6-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-{2-[3-(4-chloro-phenoxy)-phenyl]-imidazo[1,2-a]-pyridin-3-yl}-N-cyclohexyl-acetamide,
acetic acid 4-[3-(acetyl-cyclohexyl-amino)-imidazo-[1,2-a]pyrimidin-2-yl]-2-methoxy-phenyl ester,
N-[2-(5-bromo-furan-2-yl)-8-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-(2,6-dimethyl-phenyl)-N-[2-(3-hydroxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyrimidin-3-yl]-acetamide,

N-cyclohexyl-N-[2-(2,3-dichloro-phenyl)-imidazo[1,2-a]-pyridin-3-yl]-acetamide,

N-cyclohexyl-N-[2-(2,4-dichloro-phenyl)-5-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,

N-cyclohexyl-N-[2-(2,4-dichloro-phenyl)-imidazo[1,2-a]-pyrimidin-3-yl]-acetamide,

[acetyl-(2-o-tolyl-imidazo[1,2-a]pyrazin-3-yl)-amino]-acetic acid methyl ester,

N-tert-butyl-N-(6,8-dichloro-2-thiophen-2-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

N-tert-butyl-N-(5-propyl-2-thiophen-2-yl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,

{6-[acetyl-(7-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium,

N-butyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-acetamide,

(6-{acetyl-[2-(2-methoxy-phenyl)-7-methyl-imidazo-[1,2-a]pyridin-3-yl]-amino}-hexyl)-methylidyne-ammonium,

5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-6-methyl-imidazo[1,2-a]pyridin-2-yl}-furan-2-carboxylic acid,

N-butyl-N-[2-(3,4,5-trimethoxy-phenyl)-imidazo[1,2-a]-pyrazin-3-yl]-acetamide,

N-butyl-N-[2-(3-hydroxy-phenyl)-imidazo[1,2-a]pyrimidin-3-yl]-acetamide,

[acetyl-(2-o-tolyl-imidazo[1,2-a]pyrimidin-3-yl)-amino]-acetic acid methyl ester,

N-(2-benzofuran-2-yl-8-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-butyl-N-(7-methyl-2-p-tolyl-imidazo[1,2-a]pyrimidin-3-yl)-acetamide,

N-tert-butyl-N-(6,8-dibromo-2-methyl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,
{6-[acetyl-(5,7-dimethyl-2-pyridin-2-yl-imidazo[1,2-a]-pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium,
N-tert-butyl-N-[2-(2-ethoxy-naphthalen-1-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-tert-butyl-N-[2-(2-chloro-4-fluoro-phenyl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide,
cyclohexyl-[7-methyl-2-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyridin-3-yl]-amine hydrochloride,
tert-butyl-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine hydrochloride,
tert-butyl-(7-methyl-2-phenyl-imidazo[1,2-a]pyridin-3-yl)-amine hydrochloride,
cyclohexyl-(5,7-dimethyl-2-pyridin-4-yl-imidazo[1,2-a]-pyridin-3-yl)-amine hydrochloride,
(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride,
tert-butyl-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-amine hydrochloride,
[2-(2-fluorophenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride,
cyclohexyl-(7-methyl-2-phenyl-imidazo[1,2-a]pyridin-3-yl)-amine hydrochloride,
(2-furan-2-yl-7-methyl-imidazo[1,2-a]pyrimidin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride,
tert-butyl-[2-(4-nitro-phenyl)-imidazo[1,2-a]pyrazin-3-yl]-amine hydrochloride,
N-{2-[3-(4-chlorophenoxy)-phenyl]-imidazo[1,2-a]pyridin-3-yl}-N-cyclohexyl-acetamide hydrochloride,
N-cyclohexyl-N-(7-methyl-2-o-tolyl-imidazo[1,2-a]-pyridin-3-yl)-acetamide hydrochloride,

N-(2,6-dimethyl-phenyl)-N-[2-(2,4-dimethyl-phenyl)-5-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide hydrochloride,

1-acetyl-3-(acetyl-cyclohexyl-amino)-7-methyl-2-o-tolyl-imidazo[1,2-a]pyridin-1-ium) chloride hydrochloride,

cyclohexyl-(2-furan-3-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine hydrochloride,

cyclopentyl-(2-furan-3-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine hydrochloride,

[2-(4-bromo-2-fluoro-phenyl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-cyclopentyl-amine hydrochloride,

cyclopentyl-{5,7-dimethyl-2-[5-(2-nitro-phenyl)-furan-2-yl]-imidazo[1,2-a]pyridin-3-yl}-amine hydrochloride,

{2-[5-(4-chlorophenyl)-furan-2-yl]-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl}-cyclopentyl-amine hydrochloride,

cyclopentyl-(2-furan-3-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine hydrochloride,

(2-furan-3-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride,

benzyl-(7-methyl-2-thiophen-3-yl-imidazo[1,2-a]pyridin-3-yl)-amine hydrochloride,

cyclohexyl-(2-furan-3-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine hydrochloride,

(2-furan-3-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride,

(5,7-dimethyl-2-thiophen-3-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride,

[7-ethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-(2-methoxybenzyl)-amine,

(2-chlorobenzyl)-[7-ethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-amine,

[7-ethyl-2-(5-methyl-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-(2-methoxy-benzyl)-amine,
(2-chlorobenzyl)-(7-ethyl-2-furan-2-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
(3-chloro-4-fluorophenyl)-[7-ethyl-2-(5-methyl-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-amine,
(2-benzofuran-2-yl-7-ethyl-imidazo[1,2-a]pyridin-3-yl)-(3-chloro-4-fluorophenyl)-amine,
(2-benzofuran-2-yl-7-ethyl-imidazo[1,2-a]pyridin-3-yl)-(3-chlorophenyl)-amine,
(3-chloro-4-fluorophenyl)-{2-[5-(3-chloro-phenyl)-furan-2-yl]-7-ethyl-imidazo[1,2-a]pyridin-3-yl}-amine,
(3-chloro-4-fluorophenyl)-{2-[5-(2-chlorophenyl)-furan-2-yl]-7-ethyl-imidazo[1,2-a]pyridin-3-yl}-amine,
(3-chloro-4-fluorophenyl)-[2-(4,5-dimethyl-furan-2-yl)-7-ethyl-imidazo[1,2-a]pyridin-3-yl]-amine.

The compounds used according to the invention having the general structure I



I

in which R^2 represents hydrogen, W represents N and R^1, R^3, R^6, R^7, X and Y have the meanings given above, i.e. compounds having the general structure Ia, can be prepared according to the following reaction equation:



II III IV Ia

In that reaction, an amidine having the general structure II, i.e. an aminopyridine (X = CR^4 and Y = CR^5) or an aminopyrimidine (X = N and Y = CR^5) or an aminopyrazine (X = CR^4 and Y = N), wherein the radicals R^4 to R^7 are as defined for the compound having the general structure I, is reacted under suitable reaction conditions with an aldehyde having the general structure III, wherein R^3 is as defined for the compound having the general structure I, and with an isonitrile of the general formula IV, wherein R^1 is as defined for the compound having the general structure I. The reaction is preferably carried out in the presence of a small amount of an acid, especially 20% aqueous perchloric acid, in a three-component one-pot reaction, which may also be carried out in parallel synthesis semi-automatically or fully automatically. The reaction is preferably carried out in an organic solvent, especially dichloromethane or acetonitrile, at a temperature of preferably from 0°C to 80°C, especially from 15°C to 30°C.

The starting compounds having the general structures II, III and IV are commercially available (e.g. from Acros, Geel; Avocado, Port of Heysham; Aldrich, Deisenhofen; Fluka, Seelze; Lancaster, Mülheim; Maybridge, Tintagel; Merck, Darmstadt; Sigma, Deisenhofen; TCI, Japan) and/or

are readily obtainable according to processes known in the art.

For the preparation of the compounds used according to the invention of the general formula I in which R^2 does not represent hydrogen but represents $C(=O)R^9$, the compounds having the general structure in which R^2 represents H (i.e. compounds of the general formula Ia) can be reacted, according to the desired end product, with an acid halide R^9COHal wherein Hal represents fluorine, chlorine, bromine or iodine and R^9 is as defined above for the compound having the general structure I, either without a solvent or in a polar or non-polar aprotic solvent, for example dimethyl sulfoxide (DMSO), dimethylformamide (DMF), halogenated hydrocarbons, such as, for example, dichloromethane, acetonitrile, aliphatic ethers, such as tetrahydrofuran (THF) or 1,4-dioxan, or in hydrocarbons or in mixtures of those solvents, within a period of, for example, from 0.25 to 12 hours at temperatures of from 0°C to 160°C, in accordance with the following reaction scheme:



Ia $R^2 = R^9(C=O)$ **Ib**

Alternatively, the compounds of the general formula Ia can be deprotonated at the exocyclic amino nitrogen by

means of a strong base, for example an organometallic compound, such as n-butyllithium, in an aprotic solvent, such as, for example, DMF or DMSO, preferably in an ether, such as tetrahydrofuran or 1,4-dioxan, at temperatures of preferably from -70°C to +20°C. The subsequent addition of an acid halide yields the compounds of the general formula Ib, in which R^2 represents $R^9(C=O)$:



Ia Ib

Reacting compounds having the general structure Ib with an acid halide again yields the compounds having the general structure I in which W represents NR^8, i.e. compounds having the general structure Ic:



$R^2 = R^9(C=O)$ Ib Ic

The compounds used according to the invention having the general structure I can be isolated either in the form of the free base or in the form of a salt. The free base

of the compound having the general structure I used according to the invention is usually obtained after reaction according to the above-described process and subsequent conventional working-up. The free base so obtained or formed *in situ* without isolation can then be converted into the corresponding salt, for example by reaction with an inorganic or organic acid, preferably with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid or aspartic acid. The salts formed are, *inter alia*, hydrochlorides, hydrobromides, phosphates, carbonates, hydrogen carbonates, formates, acetates, oxalates, succinates, tartrates, fumarates, citrates and glutamates. Formation of the hydrochloride, which is particularly preferred, can also be effected by adding trimethylsilyl chloride (TMSCl) to the base dissolved in a suitable organic solvent, such as, for example, butan-2-one (methyl ethyl ketone).

If the compounds having the general structure I are obtained in the form of racemates or in the form of mixtures of their different enantiomers and/or diastereoisomers, such mixtures can be separated by processes which are well known in the art. Suitable methods are, *inter alia*, chromatographic separation processes, especially liquid chromatography processes under normal or elevated pressure, preferably MPLC and HPLC processes, and also fractional crystallisation processes. By means of such processes it is possible

especially to separate from one another, for example by means of HPLC on chiral phase or by means of crystallisation, individual enantiomers of diastereoisomeric salts formed with chiral acids, for example (+)-tartaric acid, (-)-tartaric acid or (+)-10-camphorsulfonic acid.

The medicaments which can be prepared by the use according to the invention of the compounds having the general structure I and which are to be used for inhibiting NOS, for the treatment of migraine or for the treatment of septic shock, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, inflammations, inflammatory pain, cerebral ischaemia, diabetes, meningitis, arteriosclerosis and/or for healing wounds, are usually pharmaceutical compositions which contain one or more pharmaceutical excipients in addition to at least one compound having the general structure I in the form of its base or of one of its pharmaceutically acceptable salts.

The pharmaceutical compositions can be in liquid, semi-solid or solid pharmaceutical dosage forms and can be administered in the form of, for example, injectable solutions, drops, juices, syrups, sprays, suspensions, granules, tablets, pellets, patches, capsules, plasters, suppositories, ointments, creams, lotions, gels, emulsions or aerosols, and, in addition to at least one compound having the general structure I, they contain, depending on the particular galenical form, pharmaceutical excipients, such as, for example, carriers, fillers, solvents, diluents, surface-active

substances, colourings, preservatives, disintegrators, glidants, lubricants, flavourings and/or binders. Such excipients may be, for example: water, ethanol, 2-propanol, glycerol, ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, glucose, fructose, lactose, saccharose, dextrose, molasses, starch, modified starch, gelatin, sorbitol, inositol, mannitol, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose, cellulose acetate, shellac, cetyl alcohol, polyvinylpyrrolidone, paraffins, waxes, pharmaceutically acceptable natural and synthetic gums, acacia gum, alginates, dextran, saturated and unsaturated fatty acids, stearic acid, magnesium stearate, zinc stearate, glyceryl stearate, sodium lauryl sulfate, edible oils, sesame oil, coconut oil, groundnut oil, soybean oil, lecithin, sodium lactate, polyoxyethylene and polyoxypropylene fatty acid esters, sorbitan fatty acid esters, sorbic acid, benzoic acid, citric acid, ascorbic acid, tannic acid, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, magnesium oxide, zinc oxide, silicon dioxide, titanium oxide, titanium dioxide, magnesium sulfate, zinc sulfate, calcium sulfate, potassium carbonate, calcium phosphate, dicalcium phosphate, potassium bromide, potassium iodide, talcum, kaolin, pectin, crospovidone, agar and bentonite.

The choice of excipients and the amounts thereof to be used depend on whether the medicament is to be administered orally, subcutaneously, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or

locally, for example to infections of the skin, the mucosa and of the eyes. For oral administration there are suitable, *inter alia*, preparations in the form of tablets, dragées, capsules, granules, drops, juices and syrups, and for parenteral and topical administration and for administration by inhalation there are suitable solutions, suspensions, readily reconstitutable dry preparations and also sprays. Compounds having the general structure I in a depot formulation in dissolved form or in a plaster, optionally with the addition of agents promoting penetration of the skin, are suitable preparations for percutaneous administration. Forms of preparation for oral or percutaneous administration may release the compounds having the general structure I in a delayed manner.

The medicaments and pharmaceutical compositions containing a compound having the general structure I are prepared by means, devices, methods and processes which are well known in the art of pharmaceutical formulation, as are described, for example, in "Remington's Pharmaceutical Sciences", ed. A.R. Gennaro, 17th ed., Mack Publishing Company, Easton, Pa. (1985), especially in Part 8, Chapter 76 to 93.

Accordingly, for a solid formulation, for example, such as a tablet, the active ingredient of the medicament, i.e. a compound having the general structure I or a pharmaceutically acceptable salt thereof, can be mixed with a pharmaceutical carrier, for example conventional tablet constituents such as maize starch, lactose, saccharose, sorbitol, talcum, magnesium stearate,

dicalcium phosphate or gum, and pharmaceutical diluents, such as, for example, water, in order to form a solid preformulation composition which contains a compound according to the invention or a pharmaceutically acceptable salt thereof in homogeneous distribution. Homogeneous distribution is here understood to mean that the active ingredient is distributed evenly throughout the entire preformulation composition, so that the latter can readily be divided into unit dose forms, such as tablets, pills or capsules, which each have the same effectiveness. The solid preformulation composition is then divided into unit dose forms. It is also possible for the tablets or pills of the medicament according to the invention or of the compositions according to the invention to be coated or otherwise compounded, in order to prepare a delayed-release dosage form. Suitable coating agents are, *inter alia*, polymeric acids and mixtures of polymeric acids with materials such as, for example, shellac, cetyl alcohol and/or cellulose acetate.

The amount of active ingredient to be administered to a patient varies and is dependent on the weight, the age and the history of past disease in the patient, and also on the mode of administration, the indication and the severity of the disease. Normally, from 0.1 to 5000 mg/kg, especially from 1 to 500 mg/kg, preferably from 2 to 250 mg/kg body weight of at least one compound having the general structure I are administered.

The assays used to determine the NOS inhibition effected by the compounds having the general structure I are described hereinbelow:

NOS assay

General

This assay enables the percentage inhibition of NO synthase by an active ingredient to be determined by measuring the NOS activity under the action of the active ingredient. NO synthase is mixed together with radioactively labelled arginine and the active ingredient under suitable conditions. After terminating the NO-forming reaction at a given time, the amount of unconverted arginine is determined directly or indirectly. A comparison of that amount with the amount of arginine that remains in a mixture of NOS and arginine without the addition of active ingredient and under otherwise identical conditions gives the % inhibition of NO synthase by the tested active ingredient. This assay can be carried out as follows:

(a) incubation of NO synthase with labelled arginine as substrate in a reaction vessel,

(b) separation of the labelled arginine from the labelled citrulline optionally formed as a product of the enzymatic reaction, at a time at which the citrulline concentration is increasing,

(c) measurement of the amount of arginine separated off in each case.

Separation is carried out over a filter plate membrane.

This NOS assay is suitable especially for "high throughput screening" (HTS) on microtitre plates (MTP).

HTS-NOS assay: General procedure

In this HTS-NOS assay, radioactive arginine is used as substrate. The assay volume can be chosen in the range from 25 µl to 250 µl, according to the type of microtitre plate (MTP). Depending on the enzyme source used, co-factors and co-enzymes are added. Incubation of the batches on this microtitre plate (assay MTP) according to step (a) is carried out at room temperature and is for 5 to 60 minutes according to the enzyme activity used (units). At the end of the incubation (step (a)), the plate is placed into a cell harvester which is equipped with a MTP having a cation-exchanger membrane as the filter base (filter MTP). All batches of the assay MTP are transferred to the filter MTP and filtered off with suction over a cation-exchanger filter plate, a paper filter charged with phosphate groups. The filter MTP is then washed with buffer or water. By means of this procedure, the arginine substrate that remains is bound to the cation exchanger, while the enzymatically formed radioactive citrulline is washed out quantitatively. After drying the filter MTP and adding scintillation liquid, the bound arginine can be counted using a scintillation counter. An uninhibited NOS reaction is reflected in low radioactivity. An inhibited enzyme reaction means that the radioactive arginine has not been converted. This means that a high level of radioactivity is found on the filter.

Materials used

- arginine, L-[2,3,4-^{3}H]-monohydrochloride; order no. NET-1123, NEN
- anhydrous $CaCl_2$; order no. 2388.1000; Merck KGaA
- 1,4-dithiothreitol (DTT), order no. 708984; ROCHE
- Na_2EDTA dihydrate; order no. 03680; FLUKA
- HEPES, order no. H-3375; SIGMA
- NADPH, tetrasodium salt; order no. 1585363; ROCHE
- TRIS; order no. 93349; FLUKA

Enzyme preparation buffer:	50 mM tris-HCl with 1 mM EDTA: The pH value of the buffer was adjusted to 7.4 at 4°C.
Incubation buffer (medium):	50 mM HEPES with 1 mM EDTA; 1.25 mM $CaCl_2$ and 1 mM dithiothreitol. The pH value of the buffer was adjusted to 7.4 at 25°C.
Washing medium:	H_2O

Enzyme preparation

Rat cerebella were used as the starting tissue. The animals were anaesthetised and sacrificed, the brain tissue, the cerebellum, was removed by dissection, 1 ml of enzyme preparation buffer was added per rat cerebellum (4°C), and disintegration was carried out using a Polytron homogeniser for 1 minute at 6000 rpm, followed by centrifugation for 15 minutes at 4°C and 20,000 g; the supernatant was then removed by

decantation and frozen in portions at -80°C (the precipitate was discarded).

Incubation batch:

96-well MTP having a well capacity of ≤ 250 µl were used.

Pipetting sequence: see Table 1:

Table 1:

Substance	**Molarity i.b.**	**µl**	***Protein i.b.**
Incubat. buffer	-	100	-
Test substance	variable; preferably 10^{-5}M	variable; preferably 20 µl	-
NADPH	0.5 mM	20	-
Enzyme (see Ex. 3)	-	variable; maximum volume of the enzyme solution = 50 µl	variable; maximum usable protein amount = 100 µg
[^{3}H] substrate	variable; preferably 50 nM	variable; preferably 10 µl	-
Final volume:		max. 250 µl	

* Protein determination according to O.H. Lowry et al.; J. Biol. Chem. **193**, 265 (1951)

i.b. = in the batch

When the pipetting operation was complete, a cover was placed on the MTP (assay MTP). Incubation at 25°C (room temperature (RT)) for from 5 to 60 minutes, according to the amount and activity of the enzyme used.

The contents of the assay MTP were then transferred with the aid of a 96-well cell harvester to a 96-well cation exchanger MTP (filter MTP) and filtered off with suction. This was followed by washing once with 200 ml of H_2O (from a bath).

The plate was then dried for 1 hour at 60°C in a drying cabinet. The underside of the filter MTP was then accurately sealed from beneath with a "back seal". 35 µl of scintillator per well were then added by means of a pipette. The upper side of the plate was also sealed with a "top seal". After waiting for 1 hour, the plate was counted using a β counter.

In the case of HTS operation, the incubation medium, the NADPH and the enzyme solution were combined before the start of the pipetting step, in order to avoid the necessity of carrying out three separate pipetting operations, which is costly in terms of time.

The results obtained for example compounds in the NOS assay are shown in Table 3.

Citrulline assay

This assay was carried out as described by D.S. Bredt and S.H. Snyder (*Proc. Natl. Acad. Sci. USA* (1990), 87, 682-685). The results obtained for example compounds in the citrulline assay are shown in Table 4.

The following Examples serve to illustrate the invention further, without limiting it thereto.

Examples:

The compounds having the general structure I were prepared according to the following general synthesis procedures (GWP):

General working procedure 1 (GWP 1)

A round-bottomed glass test tube (diameter 16 mm, length 125 mm) having a thread was provided with a stirrer and closed by means of a screw lid having a septum. The test tube was placed on a reactor block adjusted to a temperature of 15°C. The following reagents were added in succession by means of a pipette:

1.) 1 ml of a 0.1 M amidine II solution + 10 µl of 20% aqueous $HClO_4$, in dichloromethane

2.) 0.5 ml of a 0.3 M solution of the aldehyde III in dichloromethane

3.) 0.575 ml of a 0.2 M isonitrile IV solution in dichloromethane.

The reaction mixture was stirred for 12 hours at 15°C. The reaction solution was then filtered off. The test tube was rinsed twice using 1 ml of dichloromethane and 200 µl of water each time.

3 ml of a 10% NaCl solution and 1.5 ml of dichloromethane were added to the reaction mixture, and the whole was mixed thoroughly. The organic phase was separated off, and the aqueous phase was extracted again using 1.5 ml of dichloromethane. The combined organic

phases were dried over 2.4 g of $MgSO_4$ (granulated). The solvent was removed in a vacuum centrifuge.

The chemicals and solvents used were obtained commercially. Each substance was analysed by ESI-MS and/or NMR.

Examples 1 to 142 and 313 to 322 prepared according to GWP 1 were tested in an automated manner in the HTS-NOS assay. The results are shown in Table 2.

Table 2

Example No.	Compound	HTS-NOS assay: % inhibition (10 µM)	Weight calc.	Weight found
1	Tert-butyl-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-amine	63	280.37	281.3
2	Cyclohexyl-(5,7-dimethyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-amine	62	320.43	321.3
3	(5,7-Dimethyl-2-pyridin-4-yl-imidazo-[1,2-a]pyridin-3-yl)-(1,1,3,3-tetra-methyl-butyl)-amine	60	350.5	351.4
4	{6-[5,7-Dimethyl-2-(1H-pyrrol-2-yl)-imidazo[1,2-a]pyridin-3-ylamino]-hexyl}-methylidyne-ammonium	54	336.46	336.4
5	Tert-butyl-[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-amine	61	353.46	354.2
6	[2-(3,4-Dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	53	395.54	396.3
7	Cyclohexyl-(7-methyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-amine	65	306.41	307.4
8	(2-Furan-2-yl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-(1,1,3,3-tetra-methyl-butyl)-amine	52	339.48	340.4
9	(1,1,3,3-Tetramethyl-butyl)-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-amine	59	287.45	288.4
10	Cyclohexyl-(7-methyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-amine	54	319.45	320.4
11	Cyclohexyl-(7-methyl-2-thiophen-2-yl-imidazo[1,2-a]pyridin-3-yl)-amine	60	311.45	312.4
12	(5,7-Dimethyl-2-pyridin-3-yl-imidazo-[1,2-a]pyridin-3-yl)-(1,1,3,3-tetra-methyl-butyl)-amine	61	350.5	351.3
13	Cyclohexyl-[7-methyl-2-(2-trifluoro-methyl-phenyl)-imidazo[1,2-a]pyridin-3-yl]-amine	57	373.42	374.5
14	Tert-butyl-(2,5,7-trimethyl-imidazo-[1,2-a]pyridin-3-yl)-amine	67	231.34	232.2
15	(7-Methyl-2-pyridin-3-yl-imidazo-[1,2-a]pyridin-3-yl)-(1,1,3,3-tetra-methyl-butyl)-amine	59	336.48	337.4
16	Cyclohexyl-(7-methyl-2-naphthalen-1-yl-imidazo[1,2-a]pyridin-3-yl)-amine	56	355.48	356.6
17	[2-(2-Fluoro-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	51	353.48	354.3
18	(2,7-Dimethyl-imidazo[1,2-a]pyridin-3-ylamino)-acetic acid methyl ester	50	233.27	234.3

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
19	Methylidyne-[6-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-ammonium	53	334.44	334.4
20	3-(3-Tert-butylamino-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl)-phenol	64	309.41	310.3
21	Cyclohexyl-[2-(2-fluoro-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amine	53	323.41	324.5
22	Tert-butyl-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amine	68	299.46	300.3
23	Cyclohexyl-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-amine	74	306.41	307.4
24	3-(3-Tert-butylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenol	59	295.38	296.3
25	Tert-butyl-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amine	60	283.37	284.2
26	Cyclohexyl-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amine	62	309.41	310.4
27	Cyclohexyl-(5,7-dimethyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-amine	62	320.43	321.3
28	(2-Furan-2-yl-7-methyl-imidazo-[1,2-a]pyridin-3-yl)-(1,1,3,3-tetra-methyl-butyl)-amine	50	325.45	326.3
29	(7-Methyl-2-pyridin-4-yl-imidazo-[1,2-a]pyridin-3-yl)-(1,1,3,3-tetra-methyl-butyl)-amine	69	336.48	337.4
30	Butyl-(2-cyclohexyl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-amine	56	285.43	286.4
31	3-[5,7-Dimethyl-3-(1,1,3,3-tetra-methyl-butylamino)-imidazo[1,2-a]-pyridin-2-yl]-phenol	60	365.52	366.3
32	(2,6-Dimethyl-phenyl)-(5,7-dimethyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-amine	59	355.48	356.3
33	Tert-butyl-(7-methyl-2-naphthalen-1-yl-imidazo[1,2-a]pyridin-3-yl)-amine	67	329.44	330.4
34	(2,6-Dimethyl-phenyl)-[2-(2-fluoro-phenyl)-(5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine	61	359.44	360.3
35	Cyclohexyl-(2,5,7-trimethyl-imidazo-[1,2-a]pyridin-3-yl)-amine	55	257.38	258.4
36	[5,7-Dimethyl-2-(1H-pyrrol-2-yl)-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	69	338.49	339.5
37	Butyl-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amine	58	299.46	300.3
38	(5,7-Dimethyl-2-o-tolyl-imidazo-[1,2-a]pyridin-3-yl)-(1,1,3,3-tetra-methyl-butyl)-amine	60	363.54	364.3

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
39	[2-(2,3-Dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine	58	387.48	388.4
40	(2,7-Dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine	61	273.42	274.3
41	[2-(5-[1,3]Dioxolan-2-yl-furan-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	57	397.51	398.4
42	[2-(3-Bromo-thiophen-2-yl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine	55	426.38	426.3/428.2
43	(2,6-Dimethyl-phenyl)-[2-(2-fluoro-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-amine	71	345.42	346.3
44	(2-Cyclohexyl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-(1,1,3,3-tetra-methyl-butyl)-amine	71	355.56	356.3
45	[6-(2-Furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-methylidyne-ammonium	54	337.44	337.4
46	(7-Methyl-2-o-tolyl-imidazo[1,2-a]-pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine	59	349.52	350.4
47	[2-(2,3-Dichloro-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine	69	396.32	396.3/398.3
48	[2-(2,3-Dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine	68	401.5	402.3
49	Butyl-[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-amine	67	353.46	354.3
50	Methylidyne-[6-(7-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-ammonium	78	347.48	347.5
51	Tert-butyl-[5,7-dimethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-amine	59	328.37	329.4
52	Acetic acid 5-(3-cyclohexylamino-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-yl methyl ester	64	381.47	382.4
53	[2-(2-Methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	61	379.54	380.3
54	[2-(3,4-Dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine	64	387.48	388.3
55	3-(3-Butylamino-7-methyl-imidazo-[1,2-a]pyridin-2-yl)-phenol	63	295.38	296.2

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
56	(2-Benzofuran-2-yl-7-methyl-imidazo-[1,2-a]pyridin-3-yl)-(1,1,3,3-tetra-methyl-butyl)-amine	60	375.51	376.4
57	(2-Benzofuran-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(2,6-dimethyl-phenyl)-amine	57	381.47	382.4
58	Acetic acid 5-(3-cyclohexylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-yl methyl ester	64	367.44	368.4
59	[6-(5,7-Dimethyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-methylidyne-ammonium	57	348.47	348.4
60	Butyl-[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amine	52	309.41	310.3
61	{6-[2-(2-Methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino]-hexyl}-methylidyne-ammonium	73	377.51	377.3
62	{5-[5,7-Dimethyl-3-(1,1,3,3-tetra-methyl-butylamino)-imidazo[1,2-a]-pyridin-2-yl]-furan-2-yl}-methanol	55	369.5	370.4
63	(7-Methyl-2-naphthalen-1-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine	52	385.55	386.3
64	[5-(3-Tert-butylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-yl]-methanol	52	299.37	300.3
65	Tert-butyl-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-amine	62	341.41	342.4
66	(2-Benzofuran-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine	53	389.54	390.4
67	5-(3-Tert-butylamino-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-carboxylic acid	56	327.38	328.3
68	Tert-butyl-(2-furan-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-amine	57	269.34	270.4
69	Cyclohexyl-(2,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-amine	55	243.35	244.4
70	[2-(2,3-Dichlorophenyl)-8-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	52	404.38	404.3/406.2
71	(7-Methyl-2-p-tolyl-imidazo[1,2-a]-pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine	58	349.52	350.3
72	(2,6-Dimethyl-phenyl)-[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-amine	53	357.45	358.3

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
73	3-(3-Butylamino-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl)-phenol	61	309.41	310.2
74	Butyl-[2-(2,3-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amine	62	339.43	340.4
75	{6-[5,7-Dimethyl-2-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyridin-3-ylamino]-hexyl}-methylidyne-ammonium	56	415.48	415.3
76	Tert-butyl-(7-methyl-2-pyridin-2-yl-imidazo[1,2-a]pyridin-3-yl)-amine	67	280.37	281.3
77	Cyclohexyl-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amine	63	325.49	326.4
78	[2-(2,3-Dichlorophenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine	61	410.34	410.3/412.2
79	(2,6-Dimethyl-phenyl)-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-amine	66	371.48	372.3
80	{2-[5-(2-Chlorophenyl)-furan-2-yl]-7-methyl-imidazo[1,2-a]pyridin-3-yl}-(1,1,3,3-tetramethyl-butyl)-amine	52	435.99	436.4/437.2/ 438.4
81	5-[7-Methyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo[1,2-a]pyridin-2-yl]-furan-2-carboxylic acid	60	369.46	370.4
82	Cyclohexyl-[2-(2-methoxy-phenyl)-8-methyl-imidazo[1,2-a]pyridin-3-yl]-amine	62	335.45	336.4
83	3-[7-Methyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo[1,2-a]pyridin-2-yl]-phenol	60	351.49	352.4
84	[2-(2,3-Dichlorophenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	54	418.41	418.2/420.2
85	[2-(2,4-Dichlorophenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	61	404.38	404.4/406.2
86	[2-(5-Bromofuran-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	54	404.35	404.3/406.3
87	5-(3-Cyclohexylamino-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-carboxylic acid	54	353.42	354.4
88	[6-(2-Cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-methylidyne-ammonium	57	353.53	353.4
89	[2-(2,4-Dichlorophenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	68	418.41	418.3/420.2

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
90	(2-benzofuran-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-(2,6-dimethyl-phenyl)-amine	53	367.45	368.4
91	5-(3-Cyclohexylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-carboxylic acid	64	339.39	340.4
92	{6-[2-(2-Bromophenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino]-hexyl}-methylidyne-ammonium	60	426.38	425.3/427.2
93	Tert-butyl-(2-cyclohexyl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-amine	52	285.43	286.4
94	Tert-butyl-(2,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-amine	65	217.31	218.2
95	(5,7-Dimethyl-2-p-tolyl-imidazo-[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine	70	363.54	364.4
96	[2-(2,3-Dichlorophenyl)-8-methyl-imidazo[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine	55	396.32	396.3/398.3
97	Methylidyne-[6-(7-methyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-ammonium	62	347.48	347.5
98	{2-[5-(3-Chlorophenyl)-furan-2-yl]-7-methyl-imidazo[1,2-a]pyridin-3-yl}-(1,1,3,3-tetramethyl-butyl)-amine	62	435.99	436.4/438.3
99	Cyclohexyl-[7-methyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-amine	66	340.38	341.4
100	[2-(2-Bromophenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-cyclohexyl-amine	50	384.32	384.4/386.4/ 387.3
101	[2-(2-Methoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	58	365.52	366.4
102	{5-[7-Methyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo[1,2-a]pyridin-2-yl]-furan-2-yl}-methanol	59	355.48	356.5
103	(6-{2-[5-(2-Chlorophenyl)-furan-2-yl]-5-methyl-imidazo[1,2-a]pyridin-3-ylamino}-hexyl)-methylidyne-ammonium	50	433.96	433.4/435.4
104	Cyclohexyl-[5,7-dimethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-amine	63	354.4	355.4
105	Cyclohexyl-[2-(4,5-dimethyl-furan-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amine	65	323.43	324.4
106	[6-(5,7-Dimethyl-2-o-tolyl-imidazo-[1,2-a]pyridin-3-ylamino)-hexyl]-methylidyne-ammonium	60	361.51	361.4

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
107	Methylidyne-[6-(7-methyl-2-pyridin-2-yl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-ammonium	50	334.44	334.4
108	[2-(2,3-Dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	73	409.57	410.4
109	{6-[2-(3,4-Dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-ylamino]-hexyl}-methylidyne-ammonium	51	393.51	393.4
110	5-(3-Tert-butylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-thiophene-2-carboxylic acid	61	329.42	330.3
111	Cyclohexyl-(8-methyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-amine	52	306.41	307.4
112	[2-(2,3-Dichloro-phenyl)-6-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	52	404.38	404.3/406.3
113	5-(3-Butylamino-imidazo[1,2-a]-pyrazin-2-yl)-thiophene-2-carboxylic acid	54	316.38	317.3
114	Cyclohexyl-(5,7-dimethyl-2-pyridin-2-yl-imidazo[1,2-a]pyridin-3-yl)-amine	53	320.43	321.4
115	(2-Benzofuran-2-yl-8-methyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine	59	375.51	376.4
116	{6-[2-(2-Fluoro-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino]-hexyl}-methylidyne-ammonium	60	365.47	365.3
117	[2-(2,3-Dimethoxy-phenyl)-8-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine	52	395.54	396.3
118	Methylidyne-[6-(7-methyl-2-phenanthren-9-yl-imidazo[1,2-a]-pyridin-3-ylamino)-hexyl]-ammonium	56	433.57	433.5
119	5-(3-Tert-butylamino-imidazo[1,2-a]-pyrazin-2-yl)-thiophene-2-carboxylic acid	56	316.38	317.4
120	Tert-butyl-(8-methyl-2-pyridin-2-yl-imidazo[1,2-a]pyridin-3-yl)-amine	56	280.37	281.2
121	Cyclohexyl-(2-furan-2-yl-8-methyl-imidazo[1,2-a]pyridin-3-yl)-amine	53	295.38	296.4
122	Methylidyne-[6-(7-methyl-2-naphthalen-1-yl-imidazo[1,2-a]-pyridin-3-ylamino)-hexyl]-ammonium	53	383.51	383.4
123	Tert-butyl-(2-cyclohexyl-8-methyl-imidazo[1,2-a]pyridin-3-yl)-amine	53	285.43	286.4
124	(6-Methyl-2-pyridin-4-yl-imidazo-[1,2-a]pyridin-3-yl)-(1,1,3,3-tetra-methyl-butyl)-amine	68	336.48	337.4

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
125	Tert-butyl-(6-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-amine	51	280.37	281.3
126	(7-Methyl-2-pyridin-3-yl-imidazo-[1,2-a]pyrimidin-3-yl)-(1,1,3,3-tetra-methyl-butyl)-amine	50	337.47	338.4
127	5-(3-Tert-butylamino-6-methyl-imidazo[1,2-a]pyridin-2-yl)-thiophene-2-carboxylic acid	52	329.42	330.2
128	[6-(5,7-Dimethyl-2-naphthalen-1-yl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-methylidyne-ammonium	63	397.54	397.3
129	3-[3-(2,6-Dimethyl-phenylamino)-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl]-phenol	61	357.45	358.3
130	(2,6-Dimethyl-phenyl)-(8-methyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-amine	58	341.45	342.3
131	{6-[2-(3-Hydroxy-phenyl)-8-methyl-imidazo[1,2-a]pyridin-3-ylamino]-hexyl}-methylidyne-ammonium	55	349.45	349.4
132	{5-[3-(2,6-Dimethyl-phenylamino)-7-methyl-imidazo[1,2-a]pyrimidin-2-yl]-furan-2-yl}-methanol	52	348.4	349.4
133	(8-Methyl-2-p-tolyl-imidazo[1,2-a]-pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine	52	349.52	350.3
134	[2-(2,4-Dichlorophenyl)-6-methyl-imidazo[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine	56	396.32	396.2/398.2
135	Butyl-[2-(2,4-dichloro-phenyl)-6-methyl-imidazo[1,2-a]pyridin-3-yl]-amine	50	348.27	348.3/350.2
136	Butyl-[2-(4-dimethylamino-naphthalen-1-yl)-imidazo[1,2-a]-pyrazin-3-yl]-amine	56	359.47	360.5
137	{6-[2-(2-Bromo-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-ylamino]-hexyl}-methylidyne-ammonium	52	412.35	411.3/414.2
138	Butyl-[2-(2-methoxy-phenyl)-6-methyl-imidazo[1,2-a]pyridin-3-yl]-amine	52	309.41	310.3
139	(2-Cyclohexyl-8-methyl-imidazo-[1,2-a]pyridin-3-yl)-(1,1,3,3-tetra-methyl-butyl)-amine	51	341.54	342.5
140	Cyclohexyl-(7-methyl-2-pyridin-2-yl-imidazo[1,2-a]pyridin-3-yl)-amine	55	306.41	307.3
141	Cyclohexyl-(2-furan-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-amine	64	295.38	296.4
142	(2-Cyclohexyl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-ylamino)-acetic acid methyl ester	59	315.41	316.4

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
313	[7-Ethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-(2-methoxy-benzyl)-amine	32	392.42	393.9
314	(2-Chlorobenzyl)-[7-ethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-amine	47	396.83	387.3
315	[7-Ethyl-2-(5-methyl-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-(2-methoxy-benzyl)-amine	32	361.44	362.3
316	(2-Chloro-benzyl)-(7-ethyl-2-furan-2-yl-imidazo[1,2-a]pyridin-3-yl)-amine	52	351.84	352.4
317	(3-Chloro-4-fluoro-phenyl)-[7-ethyl-2-(5-methyl-furan-2-yl)-imidazo[1,2-a]-pyridin-3-yl]-amine	59	369.84	370.5
318	(2-Benzofuran-2-yl-7-ethyl-imidazo-[1,2-a]pyridin-3-yl)-(3-chloro-4-fluoro-phenyl)-amine	52	405.86	406
319	(2-Benzofuran-2-yl-7-ethyl-imidazo-[1,2-a]pyridin-3-yl)-(3-chloro-phenyl)-amine	53	387.87	388
320	(3-Chloro-4-fluorophenyl)-{2-[5-(3-chloro-phenyl)-furan-2-yl]-7-ethyl-imidazo[1,2-a]pyridin-3-yl}-amine	52	466.34	466/468
321	(3-Chloro-4-fluorophenyl)-{2-[5-(2-chlorophenyl)-furan-2-yl]-7-ethyl-imidazo[1,2-a]pyridin-3-yl}-amine	50	466.34	466/468
322	(3-Chloro-4-fluorophenyl)-[2-(4,5-dimethyl-furan-2-yl)-7-ethyl-imidazo[1,2-a]pyridin-3-yl]-amine	49	383.85	384

As comparison example, 7-nitroindazole was tested in the NOS assay with an inhibition (10 μM) of 50%.

General working procedure 2 (GWP 2):

About 0.05 mmol of the educt having the general structure I obtained according to GWP 1, in solid form, was placed in a round-bottomed test tube equipped with a stirrer. 2 ml of dichloromethane were added at 18°C, with stirring. 4 equivalents of acetyl chloride (0.2 M solution in dichloromethane) were added to the solution, and stirring was carried out for 4 hours.

The stirrer was then removed and the organic solutions were concentrated to dryness in a vacuum centrifuge at 40-50°C. An ESI-MS was recorded for characterisation purposes.

Examples 143-291 prepared according to GWP 2 were tested in the HTS-NOS assay (HTS) in an automated manner; the results are shown in Table 3.

Table 3

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
143	N-(2-Furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	68	381.51	(M-acetyl) 340.5
144	N-Tert-butyl-N-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-acetamide	59	322.41	(M-acetyl) 281.4
145	N-Tert-butyl-N-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-acetamide	66	325.41	(M-acetyl) 284.3
146	N-(5,7-Dimethyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	59	392.54	(M-acetyl) 351.4
147	N-(5,7-Dimethyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	68	392.54	(M-acetyl) 351.5
148	N-(2,6-Dimethyl-phenyl)-N-(5,7-dimethyl-2-o-tolyl-imidazo[1,2-a]-pyridin-3-yl)-acetamide	57	397.52	(M-acetyl) 356.4
149	N-(2-Furan-2-yl-7-methyl-imidazo-[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetra-methyl-butyl)-acetamide	55	367.49	(M-acetyl) 326.5
150	N-(1,1,3,3-Tetramethyl-butyl)-N-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-acetamide	60	329.48	(M-acetyl) 288.5
151	N-Cyclohexyl-N-(7-methyl-2-thiophen-2-yl-imidazo[1,2-a]pyridin-3-yl)-acetamide	65	353.48	(M-acetyl) 312.5
152	N-Tert-butyl-N-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-acetamide	66	273.37	(M-acetyl) 232.3
153	5-[3-(Acetyl-tert-butyl-amino)-imidazo[1,2-a]pyrazin-2-yl]-thiophene-2-carboxylic acid	78	358.41	(M-acetyl) 317.5
154	5-{3-[Acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-5,7-dimethyl-imidazo-[1,2-a]pyridin-2-yl}-furan-2-carboxylic acid	60	425.52	(M-acetyl) 384.6
155	N-[2-(5-Hydroxymethyl-furan-2-yl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	50	411.54	370.4; (M-acetyl) 412.4
156	N-[2-(3-Bromo-thiophen-2-yl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide	74	468.42	(M-acetyl) 426.3/428.3
157	N-Tert-butyl-N-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-acetamide	63	341.49	(M-acetyl) 300.4

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
158	Acetic acid 5-[3-(acetyl-cyclohexyl-amino)-5,7-dimethyl-imidazo[1,2-a]-pyridin-2-yl]-furan-2-yl methyl ester	54	423.51	(M-acetyl) 382.4
159	{6-[Acetyl-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium	61	379.48	(M-acetyl) 337.4
160	N-[2-(2,3-Dichloro-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide	55	438.35	(M-acetyl) 396.4/398.3
161	N-[2-(3-Bromo-thiophen-2-yl)-imidazo[1,2-a]pyridin-3-yl]-N-cyclohexyl-acetamide	51	418.36	(M-acetyl) 376.5/378.4
162	N-(5,7-Dimethyl-2-p-tolyl-imidazo-[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetra-methyl-butyl)-acetamide	67	405.58	(M-acetyl) 364.4
163	N-Cyclohexyl-N-(7-methyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-acetamide	63	348.44	(M-acetyl) 307.4
164	N-Cyclohexyl-N-[7-methyl-2-(2-trifluoromethyl-phenyl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide	61	415.45	(M-acetyl) 374.5
165	N-(6,8-Dibromo-2-furan-2-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	67	511.26	(M-acetyl) 468.3/470.2/ 472.2
166	N-(7-Methyl-2-pyridin-4-yl-imidazo-[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetra-methyl-butyl)-acetamide	61	378.51	(M-acetyl) 337.4
167	Acetic acid 5-[3-(acetyl-cyclohexyl-amino)-7-methyl-imidazo[1,2-a]-pyridin-2-yl]-furan-2-yl methyl ester	68	409.48	(M-acetyl) 368.5
168	N-(7-Methyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	56	378.51	(M-acetyl) 337.4
169	N-[2-(2,3-Dichloro-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide	57	452.38	(M-acetyl) 410.3/412.2/ 413.2
170	N-Cyclohexyl-N-[5,7-dimethyl-2-(5-methyl-furan-2-yl)-imidazo[1,2-a]-pyridin-3-yl]-acetamide	65	365.47	(M-acetyl) 324.4
171	N-Butyl-N-[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-acetamide	63	395.5	(M-acetyl) 354.4
172	N-[2-(2-Methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	62	421.58	(M-acetyl) 380.4
173	N-Cyclohexyl-N-[5,7-dimethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]-pyridin-3-yl]-acetamide	67	396.44	(M-acetyl) 355.4

Example No.	Compound	HTS-NOS assay: % inhibition (10 µM)	Weight calc.	Weight found
174	Acetyl-(2,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amino]-acetic acid methyl ester	68	275.3	(M-acetyl) 234.4
175	N-Cyclohexyl-N-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-acetamide	52	299.41	(M-acetyl) 258.4
176	5-{3-[Acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-imidazo[1,2-a]pyridin-2-yl}-thiophene-2-carboxylic acid	50	413.53	(M-acetyl) 372.5
177	N-[2-(2,4-Dichloro-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	67	460.44	(M-acetyl) 418.3/420.3/ 421.2
178	N-Cyclohexyl-N-[7-methyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-acetamide	64	382.41	(M-acetyl) 341.5
179	N-(2-Tert-butyl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-acetamide	60	363.5	(M-acetyl) 322.4
180	N-(2,6-dimethyl-phenyl)-N-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-acetamide	54	413.52	(M-acetyl) 372.4
181	N-[2-(3-Hydroxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	60	407.55	408.3; (M-acetyl) 366.4
182	N-(2,6-dimethyl-phenyl)-N-[2-(2-fluoro-phenyl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-acetamide	53	401.48	(M-acetyl) 360.4
183	5-[3-(Acetyl-tert-butyl-amino)-5-methyl-imidazo[1,2-a]pyridin-2-yl]-thiophene-2-carboxylic acid	50	371.45	(M-acetyl) 330.4
184	N-(2,6-Dimethyl-phenyl)-N-[2-(2-methoxy-phenyl)-7-methyl-imidazo-[1,2-a]pyridin-3-yl]-acetamide	51	399.49	(M-acetyl) 358.5
185	N-(7-Methyl-2-p-tolyl-imidazo[1,2-a]-pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	55	391.55	(M-acetyl) 350.4
186	5-{3-[Acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-7-methyl-imidazo-[1,2-a]pyridin-2-yl}-furan-2-carboxylic acid	65	411.5	(M-acetyl) 370.5
187	N-Cyclohexyl-N-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-acetamide	67	348.44	(M-acetyl) 307.4
188	N-[2-(5-[1,3]Dioxolan-2-yl-furan-2-yl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	50	453.58	(M-acetyl) 412.3
189	N-(2-Benzofuran-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-acetamide	63	423.51	(M-acetyl) 382.5

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
190	N-Tert-butyl-N-(2-furan-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-acetamide	69	311.38	(M-acetyl) 270.3
191	N-Tert-butyl-N-(7-methyl-2-pyridin-2-yl-imidazo[1,2-a]pyridin-3-yl)-acetamide	57	322.41	(M-acetyl) 281.3
192	N-Cyclohexyl-N-(5,7-dimethyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-acetamide	72	362.47	(M-acetyl) 321.4
193	N-[2-(2,3-Dichloro-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	55	460.44	(M-acetyl) 418.3/420.3/ 421.1
194	N-[2-(2,3-Dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	59	451.61	(M-acetyl) 410.4
195	N-{2-[3-(4-Chloro-phenoxy)-phenyl]-imidazo[1,2-a]pyridin-3-yl}-N-(2,6-dimethyl-phenyl)-acetamide	54	481.98	(M-acetyl) 440.4/441.4/ 442.4
196	N-[2-(5-[1,3]Dioxolan-2-yl-furan-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	54	439.55	(M-acetyl) 398.4
197	5-[3-(Acetyl-cyclohexyl-amino)-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl]-furan-2-carboxylic acid	70	395.45	(M-acetyl) 354.4
198	N-Tert-butyl-N-[7-methyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-acetamide	54	356.38	(M-acetyl) 314.4
199	N-[2-(2-Methoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	57	407.55	(M-acetyl) 366.4
200	N-[2-(5-Methyl-furan-2-yl)-imidazo-[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetra-methyl-butyl)-acetamide	58	367.49	(M-acetyl) 326.4/327.4
201	5-[3-(Acetyl-tert-butyl-amino)-7-methyl-imidazo[1,2-a]pyridin-2-yl]-furan-2-carboxylic acid	54	355.39	(M-acetyl) 314.4
202	N-[2-(4,5-Dimethyl-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	57	381.51	(M-acetyl) 340.6
203	N-Cyclohexyl-N-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-acetamide	60	351.44	(M-acetyl) 310.4
204	N-Tert-butyl-N-(7-methyl-2-naphthalen-1-yl-imidazo[1,2-a]-pyridin-3-yl)-acetamide	54	371.48	(M-acetyl) 330.4
205	5-{3-[Acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-imidazo[1,2-a]pyrazin-2-yl}-thiophene-2-carboxylic acid	52	414.52	(M-acetyl) 373.4

Example No.	Compound	HTS-NOS assay: % inhibition (10 µM)	Weight calc.	Weight found
206	N-Butyl-N-(2-o-tolyl-imidazo[1,2-a]-pyrimidin-3-yl)-acetamide	54	322.41	339.4/340.4
207	N-[2-(3,4-Dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide	51	429.51	(M-acetyl) 388.4
208	N-Tert-butyl-N-(7-methyl-2-phenanthren-9-yl-imidazo[1,2-a]-pyridin-3-yl)-acetamide	63	421.54	(M-acetyl) 380.5
209	N-(2,6-Dimethyl-phenyl)-N-[2-(2-fluoro-phenyl)-7-methyl-imidazo-[1,2-a]pyridin-3-yl]-acetamide	62	387.45	(M-acetyl) 346.4/347.3
210	N-[2-(2-Methoxy-phenyl)-8-methyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	53	407.55	(M-acetyl) 366.4
211	N-(2,6-Dimethyl-phenyl)-N-[2-(3-hydroxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-acetamide	73	399.49	(M-acetyl) 358.4
212	N-(2-Tert-butyl-7-methyl-imidazo-[1,2-a]pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-acetamide	68	349.47	(M-acetyl) 308.4
213	Acetic acid 4-{3-[acetyl-(2,6-dimethyl-phenyl)-amino]-6-bromo-8-methyl-imidazo[1,2-a]pyridin-2-yl}-2-methoxy-phenyl ester	69	536.43	(M-acetyl) 494.3/497.3
214	N-Tert-butyl-N-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-7-methyl-imidazo-[1,2-a]pyridin-3-yl]-acetamide	56	383.44	(M-acetyl) 336.2
215	[6-(Acetyl-{7-methyl-2-[5-(2-nitro-phenyl)-furan-2-yl]-imidazo[1,2-a]-pyridin-3-yl}-amino)-hexyl]-methylidyne-ammonium	50	486.55	487.5; (M-acetyl) 444.5
216	N-(2-Benzofuran-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	50	417.55	(M-acetyl) 376.4/377.3
217	N-(2-Benzofuran-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	63	431.57	(M-acetyl) 390.4/391.4
218	5-[3-Acetyl-tert-butyl-amino)-imidazo-[1,2-a]pyridin-2-yl]-thiophene-2-carboxylic acid	60	357.43	(M-acetyl) 316.5
219	N-(2-Cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	62	397.6	(M-acetyl) 356.5
220	N-Tert-butyl-N-[2-(5-methyl-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-acetamide	61	311.38	(M-acetyl) 270.4
221	N-Tert-butyl-N-[2-(5-methylsulfanyl-thiophen-2-yl)-imidazo[1,2-a]-pyrimidin-3-yl]-acetamide	54	360.5	(M-acetyl) 319.4

Example No.	Compound	HTS-NOS assay: % inhibition (10 µM)	Weight calc.	Weight found
222	N-[2-(4,5-Dimethyl-furan-2-yl)-5-methyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	53	395.54	(M-acetyl) 354.5
223	N-Butyl-N-[2-(2,4-dichloro-phenyl)-imidazo[1,2-a]pyrimidin-3-yl]-acetamide	62	377.27	377.4/379.4
224	N-[2-(3-Bromo-thiophen-2-yl)-6-methyl-imidazo[1,2-a]pyridin-3-yl]-N-cyclohexyl-acetamide	53	432.38	(M-acetyl) 390.4/392.4
225	5-{3-[Acetyl-(2,6-dimethyl-phenyl)-amino]-6-methyl-imidazo[1,2-a]-pyridin-2-yl}-thiophene-2-carboxylic acid	55	419.5	(M-acetyl) 378.4
226	N-Butyl-N-[2-(2,3-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide	62	381.47	382.5
227	N-Tert-butyl-N-[2-(2,3-dichloro-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetamide	54	376.28	(M-acetyl) 334.3/336.3
228	N-(2-Furan-2-yl-5-propyl-imidazo-[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	53	395.54	(M-acetyl) 354.4
229	5-[3-(Acetyl-cyclohexyl-amino)-imidazo[1,2-a]pyridin-2-yl]-thiophene-2-carboxylic acid	59	383.46	(M-acetyl) 342.5
230	5-{3-[Acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-8-methyl-imidazo-[1,2-a]pyridin-2-yl}-furan-2-carboxylic acid	52	411.5	(M-acetyl) 370.6
231	3-(Acetyl-butyl-amino)-2-pyridin-2-yl-imidazo[1,2-a]pyridine-8-carboxylic acid	52	352.39	353.5
232	{6-[Acetyl-(5,7-dimethyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium	59	390.51	(M-acetyl) 348.5
233	N-Tert-butyl-N-[2-(5-methylsulfanyl-thiophen-2-yl)-imidazo[1,2-a]pyrazin-3-yl]-acetamide	53	360.5	(M-acetyl) 319.2
234	5-[3-(Acetyl-cyclohexyl-amino)-5-methyl-imidazo[1,2-a]pyridin-2-yl]-thiophene-2-carboxylic acid	58	397.49	(M-acetyl) 356.4
235	N-[2-(5-Methylsulfanyl-thiophen-2-yl)-imidazo[1,2-a]pyrazin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	58	416.6	(M-acetyl) 375.3
236	N-[2-(2,3-Dichloro-phenyl)-5-methyl-imidazo[1,2-a]pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide	58	438.35	(M-acetyl) 396.3/398.3
237	N-Butyl-N-[2-(2-methoxy-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetamide	55	337.42	338.5

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
238	(6-{Acetyl-[2-(2-methoxy-phenyl)-6-nitro-imidazo[1,2-a]pyridin-3-yl]-amino}-hexyl)-methylidyne-ammonium	52	436.49	436.5
239	N-(2-Benzofuran-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-acetamide	52	409.48	(M-acetyl) 368.5
240	(6-{Acetyl-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-amino}-hexyl)-methylidyne-ammonium	61	419.54	(M-acetyl) 377.5
241	{6-[Acetyl-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium	62	376.48	(M-acetyl) 334.5
242	N-(6-Methyl-2-p-tolyl-imidazo[1,2-a]-pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	58	391.55	(M-acetyl) 350.4
243	Acetic acid 5-{3-[acetyl-(2,6-dimethyl-phenyl)-amino]- 5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl}-furan-2-yl methyl ester	62	445.51	(M-acetyl) 404.4
244	{Acetyl-[2-(3-hydroxy-phenyl)-6-methyl-imidazo[1,2-a]pyridin-3-yl]-amino}-acetic acid methyl ester	50	353.37	354.4; (M-acetyl) 312.4
245	N-Tert-butyl-N-[2-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetamide	56	375.39	(M-acetyl) 334.3
246	N-Butyl-N-[2-(2-chloro-4-fluoro-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetamide	55	359.83	360.4
247	N-[2-(2,4-Dichloro-phenyl)-imidazo-[1,2-a]pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide	56	424.33	(M-acetyl) 382.4/384.3
248	5-{3-[Acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-7-methyl-imidazo-[1,2-a]pyrimidin-2-yl}-furan-2-carboxylic acid	52	412.48	(M-acetyl) 371.8
249	Acetic acid 5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-imidazo-[1,2-a]pyrimidin-2-yl}-furan-2-yl methyl ester	54	426.51	(M-acetyl) 385.4
250	N-(2,7-Dimethyl-imidazo[1,2-a]-pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	58	315.46	(M-acetyl) 274.5
251	Acetic acid 4-[3-(acetyl-cyclohexyl-amino)-5-amino-7-chloro-imidazo-[1,2-a]pyrimidin-2-yl]-2-methoxy-phenyl ester	51	471.94	472.4; (M-acetyl) 430.4/432.4

Example No.	Compound	HTS-NOS assay: % inhibition (10 μM)	Weight calc.	Weight found
252	Acetic acid 4-[3-(acetyl-cyclohexyl-amino)-5,7-dimethyl-imidazo[1,2-a]-pyrimidin-2-yl]-2-methoxy-phenyl ester	53	450.53	(M-acetyl) 409.5
253	N-[6-Bromo-2-(2-chloro-6-fluoro-phenyl)-8-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-cyclohexyl-acetamide	51	478.79	(M-acetyl) 436.4/438.3/ 440.3
254	N-[2-(2-Chloro-6-fluoro-phenyl)-5-methyl-imidazo[1,2-a]pyridin-3-yl]-N-cyclohexyl-acetamide	51	399.89	(M-acetyl) 358.3
255	N-Butyl-N-[2-(2,3-dichloro-phenyl)-imidazo[1,2-a]pyrimidin-3-yl]-acetamide	65	377.27	377.4/379.4
256	N-[2-(5-Chloro-thiophen-2-yl)-imidazo[1,2-a]pyrimidin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	55	404.96	(M-acetyl) 363.3/365.3/ 367.3
257	[Acetyl-(2-cyclohexyl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-amino]-acetic acid methyl ester	56	343.42	(M-acetyl) 302.5
258	N-Tert-butyl-N-[2-(2-chloro-6-fluoro-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetamide	60	359.83	(M-acetyl) 318.3/320.3
259	N-Cyclohexyl-N-(5,7-dimethyl-2-pyridin-2-yl-imidazo[1,2-a]pyridin-3-yl)-acetamide	73	362.47	(M-acetyl) 321.4
260	Acetic acid 5-[3-(acetyl-cyclohexyl-amino)-5-methyl-imidazo[1,2-a]-pyridin-2-yl]-furan-2-yl methyl ester	51	409.48	(M-acetyl) 368.6
261	N-(2,6-Dimethyl-phenyl)-N-[6-methyl-2-(2-trifluoromethyl-phenyl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide	61	437.46	(M-acetyl) 396.4
262	N-Cyclohexyl-N-(2-furan-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-acetamide	54	337.42	(M-acetyl) 296.5
263	N-Cyclohexyl-N-(7-methyl-2-pyridin-2-yl-imidazo[1,2-a]pyridin-3-yl)-acetamide	64	348.44	349.4; (M-acetyl) 307.4
264	N-Cyclohexyl-N-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-5-methyl-imidazo-[1,2-a]pyridin-3-yl]-acetamide	50	409.48	(M-acetyl) 368.4
265	N-Tert-butyl-N-(5-propyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-acetamide	54	350.46	(M-acetyl) 309.3
266	N-Tert-butyl-N-[2-(5-methyl-thiophen-2-yl)-imidazo[1,2-a]pyrimidin-3-yl]-acetamide	53	328.43	(M-acetyl) 287.3
267	3-[Acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-2-furan-2-yl-imidazo[1,2-a]-pyridine-8-carboxylic acid	62	397.47	(M-acetyl) 356.7

Example No.	Compound	HTS-NOS assay: % inhibition (10 µM)	Weight calc.	Weight found
268	N-Tert-butyl-N-[2-(4,5-dimethyl-furan-2-yl)-6-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide	51	339.43	(M-acetyl) 298.4
269	N-{2-[3-(4-Chloro-phenoxy)-phenyl]-imidazo[1,2-a]pyridin-3-yl}-N-cyclohexyl-acetamide	51	459.97	460.4/462.4; (M-acetyl) 418.5/419.4
270	Acetic acid 4-[3-(acetyl-cyclohexyl-amino)-imidazo[1,2-a]pyrimidin-2-yl]-2-methoxy-phenyl ester	52	422.48	423.4; (M-acetyl) 381.4
271	N-[2-(5-Bromo-furan-2-yl)-8-methyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide	51	446.39	(M-acetyl) 404.4/406.3
272	N-(2,6-Dimethyl-phenyl)-N-[2-(3-hydroxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyrimidin-3-yl]-acetamide	54	400.48	359.5 (M-acetyl) 401.4
273	N-Cyclohexyl-N-[2-(2,3-dichloro-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetamide	55	402.32	(M-acetyl) 360.4/362.4
274	N-Cyclohexyl-N-[2-(2,4-dichloro-phenyl)-5-methyl-imidazo[1,2-a]-pyridin-3-yl]-acetamide	64	416.35	(M-acetyl) 374.4/376.3
275	N-Cyclohexyl-N-[2-(2,4-dichloro-phenyl)-imidazo[1,2-a]pyrimidin-3-yl]-acetamide	59	403.31	(M-acetyl) 361.4/363.3
276	[Acetyl-(2-o-tolyl-imidazo[1,2-a]-pyrazin-3-yl)-amino]-acetic acid methyl ester	50	338.36	(M-acetyl) 297.4
277	N-Tert-butyl-N-(6,8-dichloro-2-thiophen-2-yl-imidazo[1,2-a]pyridin-3-yl)-acetamide	53	382.31	(M-acetyl) 340.3/342.2
278	N-Tert-butyl-N-(5-propyl-2-thiophen-2-yl-imidazo[1,2-a]pyridin-3-yl)-acetamide	55	355.5	(M-acetyl) 340.3/342.2
279	{6-[Acetyl-(7-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium	71	389.52	389.6 (M-acetyl) 347.6
280	N-Butyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-acetamide	53	335.45	336.5; (M-acetyl) 294.5
281	(6-{Acetyl-[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amino}-hexyl)-methylidyne-ammonium	62	405.52	405.5
282	5-{3-[Acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-6-methyl-imidazo-[1,2-a]pyridin-2-yl}-furan-2-carboxylic acid	51	411.5	(M-acetyl) 370.4
283	N-Butyl-N-[2-(3,4,5-trimethoxy-phenyl)-imidazo[1,2-a]pyrazin-3-yl]-acetamide	51	398.46	399.5; (M-acetyl) 357.5

Example No.	Compound	HTS-NOS assay: % inhibition (10 µM)	Weight calc.	Weight found
284	N-Butyl-N-[2-(3-hydroxy-phenyl)-imidazo[1,2-a]pyrimidin-3-yl]-acetamide	51	324.38	325.4; (M-acetyl) 283.3
285	[Acetyl-(2-o-tolyl-imidazo[1,2-a]-pyrimidin-3-yl)-amino]-acetic acid methyl ester	51	338.36	339.3; (M-acetyl) 297.4
286	N-(2-Benzofuran-2-yl-8-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide	59	417.55	(M-acetyl) 376.4/377.4
287	N-Butyl-N-(7-methyl-2-p-tolyl-imidazo[1,2-a]pyrimidin-3-yl)-acetamide	58	336.43	337.5
288	N-Tert-butyl-N-(6,8-dibromo-2-methyl-imidazo[1,2-a]pyridin-3-yl)-acetamide	62	403.12	(M-acetyl) 362.2
289	{6-[Acetyl-(5,7-dimethyl-2-pyridin-2-yl-imidazo[1,2-a]pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium	63	390.51	(M-acetyl) 348.5
290	N-Tert-butyl-N-[2-(2-ethoxy-naphthalen-1-yl)-7-methyl-imidazo-[1,2-a]pyridin-3-yl]-acetamide	67	415.53	(M-acetyl) 374.4
291	N-Tert-butyl-N-[2-(2-chloro-4-fluoro-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetamide	53	359.83	(M-acetyl) 318.3/319.2

General working procedure 3 (GWP 3)

(Equivalents mean substance equivalents relative to the isonitrile used):

1.15 equivalents of the heterocyclic amine having the general structure II were first suspended or dissolved in dichloromethane (2 ml per mmol of isonitrile IV used) in a reaction vessel. 1.5 equivalents of aldehyde III, one equivalent of isonitrile IV and finally aqueous perchloric acid solution (20 m%; 0.098 ml per mmol of isonitrile used) were added thereto in succession, and the batch was stirred for 20 hours at room temperature.

For working up, saturated sodium chloride solution (about 5 ml per mmol of isonitrile used) and dichloromethane (about 4 ml per mmol of isonitrile used) were added, the phases were separated, and the organic phase was then extracted twice using dichloromethane (about 2 ml per mmol of isonitrile used). The combined organic phases were washed in succession with buffer solution (pH 10; Merck art. no. 1.09438.1000; about 2 ml per mmol of isonitrile used) and sat. sodium chloride solution (about 2 ml per mmol of isonitrile used), dried over sodium sulfate, filtered, concentrated *in vacuo* using a rotary evaporator and freed of solvent residues under an oil-pump vacuum.

The resulting crude product was either conveyed directly to a hydrochloride precipitation (dissolution of the crude base in about 10 ml of 2-butanone per gram of base; addition of half a molar equivalent of water, followed by 1.1 molar equivalents of chlorotrimethyl-

silane and stirring overnight), or heated to reflux with hexane (about 10 ml per mmol of isonitrile used), with stirring. If the product did not dissolve completely, it was separated off in the hot state. After cooling of the hexane solution, any solid obtained was filtered off and dried under an oil-pump vacuum. Any precipitations were treated analogously separately. The resulting filtrate was concentrated using a rotary evaporator and the residue was again dried under an oil-pump vacuum. Up to four fractions were obtained in that manner:

0: no treatment with hexane
1: residue insoluble in hexane
2: solid precipitated from hexane solution upon cooling
3: post-precipitation
4: residue from hexane solution concentrated to dryness

From the fractions obtained in each particular case, the product fraction(s) (generally the solid precipitated from the hexane solution) was/were identified by thin-layer chromatographic and/or NMR spectroscopic investigations.

Finally, a hydrochloride was precipitated from a portion of a product fraction (see above).

Examples 292-298 prepared according to GWP 3 were tested in the citrulline assay; the results are shown in Table 4. The following were also prepared by way of example according to GWP 3: cyclohexyl-(7-methyl-2-phenyl-imidazo[1,2-a]pyridin-3-yl)-amine hydrochloride, (2-furan-2-yl-7-methyl-imidazo[1,2-a]pyrimidin-3-yl)-

(1,1,3,3-tetramethyl-butyl)-amine hydrochloride and tert-butyl-[2-(4-nitro-phenyl)-imidazo[1,2-a]pyrazin-3-yl]-amine hydrochloride.

Table 4

Example No.	Name	Batch	Yield	Product fraction	Citrulline assay
		mmol isonitrile	g product fraction		IC50 (μM)
292	Cyclohexyl-[7-methyl-2-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyridin-3-yl]-amine; hydrochloride	21.3	5.93	0	2.4
293	Tert-butyl-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine; hydrochloride	18.8	4.64	0	2.8
294	Tert-butyl-(7-methyl-2-phenyl-imidazo[1,2-a]-pyridin-3-yl)-amine; hydrochloride	54.1	9.06	2	2.4
295	Cyclohexyl-(5,7-dimethyl-2-pyridin-4-yl-imidazo[1,2-a]-pyridin-3-yl)-amine; hydrochloride	50.4	12.2	2	9.2
296	(2-Furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine; hydrochloride	47.9	13.9	4	2.5
297	Tert-butyl-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-amine; hydrochloride	48.1	10.5	2 + 4	9.2
298	[2-(2-Fluorophenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine; hydrochloride	43.1	15.9	4	4.3
299	Cyclohexyl-(7-methyl-2-phenyl-imidazo[1,2-a]-pyridin-3-yl)-amine; hydrochloride	5.00	1.64	2	
300	(2-Furan-2-yl-7-methyl-imidazo[1,2-a]pyrimidin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine; hydrochloride	43.1	10.2	2 + 3	
301	Tert-butyl-[2-(4-nitro-phenyl)-imidazo[1,2-a]-pyrazin-3-yl]-amine; hydrochloride	48.1	15.1	2	

As comparison example, the NOS inhibitor 7-nitroindazole known from the prior art, having an IC_{50} value of 5.23 µM, was tested in the citrulline assay.

The compounds of Examples 302 to 312 were also prepared according to GWP 3 and tested in the above-described NOS assay for % inhibition. The results are shown in Table 5.

Table 5

Example No.	Name	NOS assay	Batch	Yield	Product fraction
		% inhibition	mmol isonitrile	g product fraction	
302	Cyclohexyl-(2-furan-3-yl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-amine hydrochloride	54	9.2	1.9	2
303	Cyclopentyl-(2-furan-3-yl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-amine hydrochloride	57	10.5	2.1	2
304	[2-(4-Bromo-2-fluoro-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-cyclopentyl-amine hydrochloride	56	6.3	1.9	4
305	Cyclopentyl-{5,7-dimethyl-2-[5-(2-nitro-phenyl)-furan-2-yl]-imidazo[1,2-a]pyridin-3-yl}-amine hydrochloride	55	6.3	3	2
306	{2-[5-(4-Chlorophenyl)-furan-2-yl]-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl}-cyclopentyl-amine hydrochloride	73	6.7	1.7	2
307	Cyclopentyl-(2-furan-3-yl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-amine hydrochloride	57	10.5	2.6	4

Example No.	Name	NOS assay	Batch	Yield	Product fraction
		% inhibition	mmol isonitrile	g product fraction	
308	(2-Furan-3-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride	50	25.1	5.6	2
309	Benzyl-(7-methyl-2-thiophen-3-yl-imidazo-[1,2-a]pyridin-3-yl)-amine hydrochloride	45	21.3	4.1	2
310	Cyclohexyl-(2-furan-3-yl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-amine hydrochloride	52	22.9	5.2	2
311	(2-Furan-3-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride	45	25.1	2.9	2
312	(5,7-Dimethyl-2-thiophen-3-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride	74	18	4.6	4

General working procedure 4 (GWP 4):

The starting material (product fraction) obtained according to GWP 3 was placed in a reaction vessel in tetrahydrofuran (about 3 ml per mmol of starting material); 1.10 substance equivalents of n-butyllithium solution in hexane (1.6 mol/l) were added dropwise, with stirring, at from -15 to -5°C, and stirring was continued for one hour. 1.05 substance equivalents of the acetyl chloride were then added dropwise, and stirring was carried out overnight with heating at room temperature.

For working up, cooling to 0 to 5°C was carried out, and semi-saturated ammonium chloride solution (about 1.5 ml per mmol of starting material) was added. Extraction was carried out three times with ether (about 1.5 ml per mmol of starting material), and the combined extracts

were dried over sodium sulfate, filtered and concentrated.

After thin-layer chromatographic and/or NMR spectroscopic investigation, a portion of the product so obtained was conveyed to a hydrochloride precipitation according to GWP 3.

The compounds prepared by way of example according to GWP 4 are N-{2-[3-(4-chlorophenoxy)-phenyl]-imidazo-[1,2-a]pyridin-3-yl}-N-cyclohexyl-acetamide hydrochloride, N-cyclohexyl-N-(7-methyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-acetamide hydrochloride and N-(2,6-dimethyl-phenyl)-N-[2-(2,4-dimethyl-phenyl)-5-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide hydrochloride.

General working procedure 5 (GWP 5):

The starting material obtained according to GWP 4 was placed in a reaction vessel; ten substance equivalents of the respective acid halide were added, with stirring, and stirring was carried out for one hour at 40°C.

The reaction mixture was taken up in a small amount of dichloromethane, and the product was precipitated by addition of ether and, optionally, hexane, and was then recrystallised.

Owing to the water content of the solvents used, the desired product was generally obtained by this procedure in the form of the hydrohalide or, alternatively, was

conveyed to a hydrochloride precipitation according to GWP 3.

1-Acetyl-3-(acetyl-cyclohexyl-amino)-7-methyl-2-o-tolyl-imidazo[1,2-a]pyridin-1-ium) chloride hydrochloride was prepared by way of example according to GWP 5.

Pharmaceutical formulation for the use according to the invention

1 g of the hydrochloride of (5,7-dimethyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine was dissolved at room temperature in 1 litre of water for injection purposes and then adjusted to isotonic conditions by addition of sodium chloride.

An isotonic solution of 1 g of (5,7-dimethyl-2-thiophen-3-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride in 1 litre of water was prepared in the same manner.

- Amended claims 16.12.2002 -

Claims

1. Use of a compound having the general structure I or of a pharmaceutically acceptable salt thereof



I

wherein

X represents CR^4 or N,

Y represents CR^5 or N and

X and Y do not simultaneously represent N,

W represents N or NR^8,

R^1 represents C_{1-12}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl, wherein heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, heteroaryl, wherein heteroaryl is

unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-aryl or C_{1-8}-alkyl-heteroaryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl is unsubstituted or mono- or poly-substituted and heteroaryl is unsubstituted or mono- or poly-substituted,

R^2 represents hydrogen or $C(=O)R^9$,

R^3 represents C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl, wherein heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, heteroaryl, wherein heteroaryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-C_{3-8}-cycloalkyl, C_{1-8}-alkyl-heterocyclyl, C_{1-8}-alkyl-aryl or C_{1-8}-alkyl-heteroaryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl is saturated or unsaturated and is unsubstituted or mono-

or poly-substituted, aryl is unsubstituted or mono- or poly-substituted and heteroaryl is unsubstituted or mono- or poly-substituted,

R^4, R^5, R^6 and R^7 each independently of the others represents hydrogen or C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, F, Cl, Br, I, CN, NO_2, NH_2, $C(=O)R^9$, CO_2H, CO_2R^{10}, OH or OR^{11}, or

R^4 and R^5 or R^5 and R^6 or R^6 and R^7 represent a four-membered saturated or unsaturated hydrocarbon bridge having zero, 1, 2 or 3 hetero atoms selected from the group containing N, O and S, and the other radicals of R^4, R^5, R^6 and R^7 represent hydrogen,

R^8 represents $C(=O)R^9$,

R^9 represents C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl, wherein heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or

poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, heteroaryl, wherein heteroaryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-aryl or C_{1-8}-alkyl-heteroaryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl is unsubstituted or mono- or poly-substituted and heteroaryl is unsubstituted or mono- or poly-substituted, and

R^{10} and R^{11} each independently of the other represents C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-aryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted and aryl is unsubstituted or mono- or poly-substituted,

in the preparation of a medicament for the treatment of inflammatory pain.

2. Use of a compound having the general structure I or of a pharmaceutically acceptable salt thereof

- Amended claims 16.12.2002 -



I

wherein

X represents CR^4 or N,

Y represents CR^5 or N and

X and Y do not simultaneously represent N,

W represents N or NR^8,

R^1 represents C_{1-12}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl, wherein heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, heteroaryl, wherein heteroaryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-aryl or C_{1-8}-alkyl-heteroaryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is

unsubstituted or mono- or poly-substituted, aryl is unsubstituted or mono- or poly-substituted and heteroaryl is unsubstituted or mono- or poly-substituted,

R^2 represents hydrogen or $C(=O)R^9$,

R^3 represents C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl, wherein heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, heteroaryl, wherein heteroaryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-C_{3-8}-cycloalkyl, C_{1-8}-alkyl-heterocyclyl, C_{1-8}-alkyl-aryl or C_{1-8}-alkyl-heteroaryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl is unsubstituted or mono- or poly-substituted and heteroaryl is unsubstituted or mono- or poly-substituted,

- Amended claims 16.12.2002 -

R^4, R^5, R^6 and R^7 each independently of the others represents hydrogen or C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, F, Cl, Br, I, CN, NO_2, NH_2, $C(=O)R^9$, CO_2H, CO_2R^{10}, OH or OR^{11}, or

R^4 and R^5 or R^5 and R^6 or R^6 and R^7 represent a four-membered saturated or unsaturated hydrocarbon bridge having zero, 1, 2 or 3 hetero atoms selected from the group containing N, O and S, and the other radicals of R^4, R^5, R^6 and R^7 represent hydrogen,

R^8 represents $C(=O)R^9$,

R^9 represents C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl, wherein heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, heteroaryl, wherein heteroaryl is unsubstituted or mono- or poly-substituted,

- Amended claims 16.12.2002 -

C_{1-8}-alkyl-aryl or C_{1-8}-alkyl-heteroaryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl is unsubstituted or mono- or poly-substituted and heteroaryl is unsubstituted or mono- or poly-substituted, and

R^{10} and R^{11} each independently of the other represents C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-aryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted and aryl is unsubstituted or mono- or poly-substituted,

in the preparation of a medicament for the treatment of migraine.

3. Use of a compound having the general structure I or of a pharmaceutically acceptable salt thereof

- Amended claims 16.12.2002 -



I

wherein

X represents CR^4 or N,

Y represents CR^5 or N and

X and Y do not simultaneously represent N,

W represents N or NR^8,

R^1 represents C_{1-12}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl, wherein heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, heteroaryl, wherein heteroaryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-aryl or C_{1-8}-alkyl-heteroaryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is

unsubstituted or mono- or poly-substituted, aryl is unsubstituted or mono- or poly-substituted and heteroaryl is unsubstituted or mono- or poly-substituted,

R^2 represents hydrogen or $C(=O)R^9$,

R^3 represents C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl, wherein heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, heteroaryl, wherein heteroaryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-C_{3-8}-cycloalkyl, C_{1-8}-alkyl-heterocyclyl, C_{1-8}-alkyl-aryl or C_{1-8}-alkyl-heteroaryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl is unsubstituted or mono- or poly-substituted and heteroaryl is unsubstituted or mono- or poly-substituted,

R^4, R^5, R^6 and R^7 each independently of the others represents hydrogen or C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, F, Cl, Br, I, CN, NO_2, NH_2, $C(=O)R^9$, CO_2H, CO_2R^{10} or OH, or

R^4 and R^5 or R^5 and R^6 or R^6 and R^7 represent a four-membered saturated or unsaturated hydrocarbon bridge having zero, 1, 2 or 3 hetero atoms selected from the group containing N, O and S, and the other radicals of R^4, R^5, R^6 and R^7 represent hydrogen,

R^8 represents $C(=O)R^9$,

R^9 represents C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, heterocyclyl, wherein heterocyclyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, heteroaryl, wherein heteroaryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-aryl or C_{1-8}-alkyl-heteroaryl,

wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl is unsubstituted or mono- or poly-substituted and heteroaryl is unsubstituted or mono- or poly-substituted, and

R^{10} represents C_{1-8}-alkyl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is saturated or unsaturated and is unsubstituted or mono- or poly-substituted, aryl, wherein aryl is unsubstituted or mono- or poly-substituted, C_{1-8}-alkyl-aryl, wherein alkyl is straight-chain or branched and is saturated or unsaturated and is unsubstituted or mono- or poly-substituted and aryl is unsubstituted or mono- or poly-substituted,

in the preparation of a medicament for the treatment of multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, cerebral ischaemia, diabetes, meningitis, arteriosclerosis and/or for healing wounds.

4. Use according to any one of claims 1, 2 or 3, characterised in that

R^1 represents methyl, ethyl, n-propyl, 2-propyl, n-butyl, tert-butyl, n-hexyl, n-octyl, 1,1,3,3-tetramethylbutyl, CH_2aryl, wherein aryl is unsubstituted or mono- or poly-substituted, CH_2CO_2-C_{1-6}-alkyl, wherein alkyl is straight-chain or branched, $CH_2PO(O\text{-}C_{1-6}\text{-alkyl})_2$, wherein alkyl is straight-chain or branched, $CH_2SiR^{12}R^{13}R^{14}$, CH_2CH_2-morpholin-4-yl, $(CH_2)_n$-NC, wherein n = 2, 3, 4, 5 or 6, C_{3-8}-cycloalkyl, wherein cycloalkyl is unsubstituted or mono- or poly-substituted, or phenyl, wherein phenyl is unsubstituted or mono- or poly-substituted,

R^2 represents H or C(=O)-C_{1-4}-alkyl,

R^3 represents methyl, ethyl, n-propyl, 2-propyl, n-butyl, tert-butyl, cyclopropyl, cyclopentyl or cyclohexyl, which are unsubstituted or mono- or poly-substituted, phenyl, wherein phenyl is unsubstituted or mono- or poly-substituted, 1-naphthyl or 2-naphthyl, wherein naphthyl is unsubstituted or mono- or poly-substituted, 9-phenanthrenyl, pyrrol-2-yl, pyrrol-3-yl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, wherein pyrrolyl or pyridinyl are unsubstituted or mono- or poly-substituted, furan-2-yl or furan-3-yl, wherein furanyl is unsubstituted or mono- or poly-substituted, thien-2-yl or thien-3-yl, wherein thienyl is unsubstituted or mono- or poly-substituted, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, wherein imidazolyl is unsubstituted or mono- or poly-substituted, thiazol-2-yl,

thiazol-4-yl, thiazol-5-yl, wherein thiazolyl is unsubstituted or mono- or poly-substituted, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, wherein oxazolyl is unsubstituted or mono- or poly-substituted, isooxazol-3-yl, isooxazol-4-yl, isooxazol-5-yl, wherein isooxazolyl is unsubstituted or mono- or poly-substituted, indol-2-yl, benzofuran-2-yl or benzofuran-3-yl,

R^4, R^5, R^6 and R^7 each independently of the others represents H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, tert-butyl, CF_3, F, Cl, Br, I, CO_2H, CO_2methyl, CO_2ethyl, $C(=O)CH_3$ or NO_2, or R^6 and R^7 form the hydrocarbon bridge -CH=CH-CH=CH-,

R^8 represents $C(=O)CH_3$ and

R^{12}, R^{13} and R^{14} each independently of the others represents C_{1-6}-alkyl, wherein alkyl is straight-chain or branched and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is unsubstituted or mono- or poly-substituted, or phenyl, wherein phenyl is unsubstituted or mono- or poly-substituted.

5. Use according to claim 4, characterised in that

R^1 represents methyl, ethyl, n-propyl, 2-propyl, n-butyl, tert-butyl, n-hexyl, n-octyl, 1,1,3,3-tetramethylbutyl, CH_2aryl, wherein aryl is unsubstituted or mono- or poly-substituted, CH_2CO_2-C_{1-6}-alkyl, wherein alkyl is straight-chain or branched, $CH_2PO(O\text{-}C_{1-6}\text{-alkyl})_2$, wherein alkyl is straight-chain or branched, $CH_2SiR^{12}R^{13}R^{14}$, CH_2CH_2-morpholin-4-yl, $(CH_2)_n$-NC, wherein n = 2, 3, 4, 5

or 6, C_{3-8}-cycloalkyl, wherein cycloalkyl is unsubstituted or mono- or poly-substituted, or phenyl, wherein phenyl is unsubstituted or mono- or poly-substituted,

R^2 represents H or C(=O)-C_{1-4}-alkyl,

R^3 represents methyl, ethyl, n-propyl, 2-propyl, n-butyl, tert-butyl, cyclopropyl, cyclopentyl or cyclohexyl, which, independently of one another, are unsubstituted or mono- or poly-substituted, phenyl, wherein phenyl is unsubstituted or monosubstituted or polysubstituted by identical or different substituents selected from methyl, ethyl, n-propyl, prop-2-yl, n-butyl, sec-butyl, tert-butyl, isobutyl, CF_3, OH, Omethyl, Oethyl, F, Cl, Br, I, CN, NO_2, 4-chlorophenoxy, acetoxy and dimethylamino; 1-naphthyl or 2-naphthyl, wherein naphthyl is unsubstituted or monosubstituted or polysubstituted by identical or different substituents selected from methyl, ethyl, n-propyl, prop-2-yl, n-butyl, sec-butyl, tert-butyl, isobutyl, CF_3, OH, Omethyl, Oethyl, F, Cl, Br, I, CN, NO_2, 4-chlorophenoxy, acetoxy and dimethylamino; 9-phenanthrenyl, pyrrol-2-yl, pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, wherein pyridinyl is unsubstituted or monosubstituted or polysubstituted by identical or different substituents selected from methyl, ethyl, n-propyl, prop-2-yl, n-butyl, sec-butyl, tert-butyl, isobutyl, CF_3, OH, Omethyl, Oethyl, F, Cl, Br, I, CN, NO_2, 4-chlorophenoxy, acetoxy, dimethylamino, carboxy, carboxymethyl, carboxyethyl, hydroxymethyl, chlorophenyl,

nitrophenyl, [1,3]-dioxolan and methylsulfanyl; furan-2-yl or furan-3-yl, wherein furanyl is unsubstituted or monosubstituted or polysubstituted by identical or different substituents selected from methyl, ethyl, n-propyl, prop-2-yl, n-butyl, sec-butyl, tert-butyl, isobutyl, CF_3, OH, Omethyl, Oethyl, F, Cl, Br, I, CN, NO_2, 4-chlorophenoxy, acetoxy, dimethylamino, carboxy, carboxymethyl, carboxyethyl, hydroxymethyl, chlorophenyl, nitrophenyl, [1,3]-dioxolan and methylsulfanyl; thien-2-yl or thien-3-yl, wherein thienyl is unsubstituted or monosubstituted or polysubstituted by identical or different substituents selected from methyl, ethyl, n-propyl, prop-2-yl, n-butyl, sec-butyl, tert-butyl, isobutyl, CF_3, OH, Omethyl, Oethyl, F, Cl, Br, I, CN, NO_2, 4-chlorophenoxy, acetoxy, dimethylamino, carboxy, carboxymethyl, carboxyethyl, hydroxymethyl, chlorophenyl, nitrophenyl, [1,3]-dioxolan and methylsulfanyl; indol-2-yl, benzofuran-2-yl or benzofuran-3-yl,

R^4, R^5, R^6 and R^7 each independently of the others represents H, methyl, ethyl, n-propyl, 2-propyl, n-butyl, tert-butyl, CF_3, F, Cl, Br, I, CO_2H, CO_2methyl, CO_2ethyl, $C(=O)CH_3$ or NO_2, or R^6 and R^7 form the hydrocarbon bridge -CH=CH-CH=CH-,

R^8 represents $C(=O)CH_3$ and

R^{12}, R^{13} and R^{14} each independently of the others represents C_{1-6}-alkyl, wherein alkyl is straight-chain or branched and is unsubstituted or mono- or poly-substituted, C_{3-8}-cycloalkyl or CH_2-C_{3-8}-cycloalkyl, wherein cycloalkyl is unsubstituted or

mono- or poly-substituted, or phenyl, wherein phenyl is unsubstituted or mono- or poly-substituted.

6. Use according to claim 5, characterised in that

R^1 represents methyl, n-butyl, 1,1,3,3-tetramethylbutyl, benzyl, 2-chlorobenzyl, 2-methoxybenzyl, $CH_2CO_2CH_3$, $(CH_2)_6$-NC, cyclopentyl, cyclohexyl, phenyl, 2,6-dimethylphenyl, 3-chlorophenyl or 3-chloro-4-fluorophenyl,

R^2 represents H or $C(=O)CH_3$,

R^3 represents methyl, tert-butyl, cyclohexyl, phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-hydroxyphenyl, 2-methoxyphenyl, 3-hydroxyphenyl, 3-methoxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl, 3-(4-chlorophenoxy)-phenyl, 2,4-dimethylphenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 3-methoxy-4-acetoxyphenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2-chloro-4-fluorophenyl, 2-chloro-6-fluorophenyl, 4-bromo-2-fluorophenyl, 3,4,5-trimethoxyphenyl, 1-naphthyl, 2-ethoxy-naphth-1-yl, 4-dimethylamino-napth-1-yl, 9-phenanthrenyl, pyrrol-2-yl, N-methylpyrrol-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, furan-2-yl, furan-3-yl, 5-methyl-furan-2-yl, 4,5-dimethyl-furan-2-yl, 5-hydroxymethyl-furan-2-yl, 5-acetoxymethyl-furan-2-yl, 5-carboxy-furan-2-yl, 5-[1,3]-dioxolan-

furan-2-yl, 3-bromo-furan-2-yl, 5-bromo-furan-2-yl, 5-nitro-furan-2-yl, 5-(2-nitrophenyl)-furan-2-yl, 5-(2-chlorophenyl)-furan-2-yl, 5-(3-chloro-phenyl)-furan-2-yl, 5-(3-chlorophenyl)-furan-3-yl, 5-(4-chlorophenyl)-furan-2-yl, benzo[b]furan-2-yl, thien-2-yl, thien-3-yl, 5-methyl-thien-2-yl, 5-carboxy-thien-2-yl, 3-bromo-thien-2-yl, 5-chloro-thien-2-yl or 5-methylsulfanyl-thien-2-yl,

R^4 represents H, CH_3, Cl, Br or CO_2H,

R^5 represents H, CH_3, C_2H_5 or Cl,

R^6 represents H, CH_3, Cl, Br or NO_2,

R^7 represents H, CH_3 or n-C_3H_7 and

R^8 represents $C(=O)CH_3$.

7. Use according to claim 6, characterised in that R^4 and R^6 represent H, R^5 represents H, CH_3 or C_2H_5 and R^7 represents H or CH_3.

8. Use according to any one of claims 1, 2 or 3, characterised in that the compound having the general structure I is selected from the group containing:
tert-butyl-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
cyclohexyl-(5,7-dimethyl-2-pyridin-4-yl-imidazo-[1,2-a]pyridin-3-yl)-amine,
(5,7-dimethyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
{6-[5,7-dimethyl-2-(1H-pyrrol-2-yl)-imidazo[1,2-a]-pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,
tert-butyl-[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-amine,

[2-(3,4-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
cyclohexyl-(7-methyl-2-pyridin-4-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
(1,1,3,3-tetramethyl-butyl)-(2,5,7-trimethyl-imidazo-[1,2-a]pyridin-3-yl)-amine,
cyclohexyl-(7-methyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-amine,
cyclohexyl-(7-methyl-2-thiophen-2-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
(5,7-dimethyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
cyclohexyl-[7-methyl-2-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyridin-3-yl]-amine,
tert-butyl-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-amine,
(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
cyclohexyl-(7-methyl-2-naphthalen-1-yl-imidazo-[1,2-a]pyridin-3-yl)-amine,
[2-(2-fluoro-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
(2,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino)-acetic acid methyl ester,
methylidyne-[6-(7-methyl-2-pyridin-3-yl-imidazo-[1,2-a]pyridin-3-ylamino)-hexyl]-ammonium,
3-(3-tert-butylamino-5,7-dimethyl-imidazo[1,2-a]-pyridin-2-yl)-phenol,
cyclohexyl-[2-(2-fluoro-phenyl)-7-methyl-imidazo-[1,2-a]pyridin-3-yl]-amine,

tert-butyl-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine,
cyclohexyl-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
3-(3-tert-butylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenol,
tert-butyl-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine,
cyclohexyl-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine,
cyclohexyl-(5,7-dimethyl-2-pyridin-3-yl-imidazo-[1,2-a]pyridin-3-yl)-amine,
(2-furan-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
(7-methyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
butyl-(2-cyclohexyl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-amine,
3-[5,7-dimethyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo[1,2-a]pyridin-2-yl]-phenol,
(2,6-dimethyl-phenyl)-(5,7-dimethyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-amine,
tert-butyl-(7-methyl-2-naphthalen-1-yl-imidazo-[1,2-a]pyridin-3-yl)-amine,
(2,6-dimethyl-phenyl)-[2-(2-fluoro-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-amine,
cyclohexyl-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-amine,
[5,7-dimethyl-2-(1H-pyrrol-2-yl)-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
butyl-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine,

(5,7-dimethyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,

[2-(2,3-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,

(2,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,

[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,

[2-(3-bromo-thiophen-2-yl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,

(2,6-dimethyl-phenyl)-[2-(2-fluoro-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amine,

(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,

[6-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-methylidyne-ammonium,

(7-methyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,

[2-(2,3-dichloro-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,

[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,

butyl-[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-amine,

methylidyne-[6-(7-methyl-2-p-tolyl-imidazo[1,2-a]-pyridin-3-ylamino)-hexyl]-ammonium,

tert-butyl-[5,7-dimethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-amine,

acetic acid 5-(3-cyclohexylamino-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-yl methyl ester,

[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
[2-(3,4-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,
3-(3-butylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenol,
(2-benzofuran-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
(2-benzofuran-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-(2,6-dimethyl-phenyl)-amine,
acetic acid 5-(3-cyclohexylamino-7-methyl-imidazo-[1,2-a]pyridin-2-yl)-furan-2-yl methyl ester,
[6-(5,7-dimethyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-ylamino)-hexyl]-methylidyne-ammonium,
butyl-[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-amine,
{6-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,
{5-[5,7-dimethyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo[1,2-a]pyridin-2-yl]-furan-2-yl}-methanol,
(7-methyl-2-naphthalen-1-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
[5-(3-tert-butylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-yl]-methanol,
tert-butyl-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amine,
(2-benzofuran-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
5-(3-tert-butylamino-5,7-dimethyl-imidazo[1,2-a]-pyridin-2-yl)-furan-2-carboxylic acid,
tert-butyl-(2-furan-2-yl-7-methyl-imidazo[1,2-a]-pyridin-3-yl)-amine,

cyclohexyl-(2,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amine,

[2-(2,3-dichlorophenyl)-8-methyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,

(7-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,

(2,6-dimethyl-phenyl)-[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amine,

3-(3-butylamino-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl)-phenol,

butyl-[2-(2,3-dimethoxy-phenyl)-7-methyl-imidazo-[1,2-a]pyridin-3-yl]-amine,

{6-[5,7-dimethyl-2-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,

tert-butyl-(7-methyl-2-pyridin-2-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,

cyclohexyl-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine,

[2-(2,3-dichlorophenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,

(2,6-dimethyl-phenyl)-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-amine,

{2-[5-(2-chlorophenyl)-furan-2-yl]-7-methyl-imidazo[1,2-a]pyridin-3-yl}-(1,1,3,3-tetramethyl-butyl)-amine,

5-[7-methyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo[1,2-a]pyridin-2-yl]-furan-2-carboxylic acid,

cyclohexyl-[2-(2-methoxy-phenyl)-8-methyl-imidazo-[1,2-a]pyridin-3-yl]-amine,

3-[7-methyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo[1,2-a]pyridin-2-yl]-phenol,

[2-(2,3-dichlorophenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
[2-(2,4-dichlorophenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
[2-(5-bromofuran-2-yl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
5-(3-cyclohexylamino-5,7-dimethyl-imidazo[1,2-a]-pyridin-2-yl)-furan-2-carboxylic acid,
[6-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-methylidyne-ammonium,
[2-(2,4-dichlorophenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
(2-benzofuran-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-(2,6-dimethyl-phenyl)-amine,
5-(3-cyclohexylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-furan-2-carboxylic acid,
{6-[2-(2-bromophenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,
tert-butyl-(2-cyclohexyl-7-methyl-imidazo[1,2-a]-pyridin-3-yl)-amine,
tert-butyl-(2,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amine,
(5,7-dimethyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
[2-(2,3-dichlorophenyl)-8-methyl-imidazo[1,2-a]-pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,
methylidyne-[6-(7-methyl-2-o-tolyl-imidazo[1,2-a]-pyridin-3-ylamino)-hexyl]-ammonium,
{2-[5-(3-chlorophenyl)-furan-2-yl]-7-methyl-imidazo-[1,2-a]pyridin-3-yl}-(1,1,3,3-tetramethyl-butyl)-amine,

cyclohexyl-[7-methyl-2-(5-nitro-furan-2-yl)-imidazo-[1,2-a]pyridin-3-yl]-amine,
[2-(2-bromophenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-cyclohexyl-amine,
[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
{5-[7-methyl-3-(1,1,3,3-tetramethyl-butylamino)-imidazo[1,2-a]pyridin-2-yl]-furan-2-yl}-methanol,
(6-{2-[5-(2-chlorophenyl)-furan-2-yl]-5-methyl-imidazo[1,2-a]pyridin-3-ylamino}-hexyl)-methylidyne-ammonium,
cyclohexyl-[5,7-dimethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-amine,
cyclohexyl-[2-(4,5-dimethyl-furan-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-amine,
[6-(5,7-dimethyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-ylamino)-hexyl]-methylidyne-ammonium,
methylidyne-[6-(7-methyl-2-pyridin-2-yl-imidazo-[1,2-a]pyridin-3-ylamino)-hexyl]-ammonium,
[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
{6-[2-(3,4-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,
5-(3-tert-butylamino-7-methyl-imidazo[1,2-a]pyridin-2-yl)-thiophene-2-carboxylic acid,
cyclohexyl-(8-methyl-2-pyridin-4-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
[2-(2,3-dichloro-phenyl)-6-methyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
5-(3-butylamino-imidazo[1,2-a]pyrazin-2-yl)-thiophene-2-carboxylic acid,

cyclohexyl-(5,7-dimethyl-2-pyridin-2-yl-imidazo-[1,2-a]pyridin-3-yl)-amine,
(2-benzofuran-2-yl-8-methyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
{6-[2-(2-fluoro-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,
[2-(2,3-dimethoxy-phenyl)-8-methyl-imidazo[1,2-a]-pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine,
methylidyne-[6-(7-methyl-2-phenanthren-9-yl-imidazo-[1,2-a]pyridin-3-ylamino)-hexyl]-ammonium,
5-(3-tert-butylamino-imidazo[1,2-a]pyrazin-2-yl)-thiophene-2-carboxylic acid,
tert-butyl-(8-methyl-2-pyridin-2-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
cyclohexyl-(2-furan-2-yl-8-methyl-imidazo[1,2-a]-pyridin-3-yl)-amine,
methylidyne-[6-(7-methyl-2-naphthalen-1-yl-imidazo-[1,2-a]pyridin-3-ylamino)-hexyl]-ammonium,
tert-butyl-(2-cyclohexyl-8-methyl-imidazo[1,2-a]-pyridin-3-yl)-amine,
(6-methyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
tert-butyl-(6-methyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,
(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyrimidin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,
5-(3-tert-butylamino-6-methyl-imidazo[1,2-a]pyridin-2-yl)-thiophene-2-carboxylic acid,
[6-(5,7-dimethyl-2-naphthalen-1-yl-imidazo[1,2-a]-pyridin-3-ylamino)-hexyl]-methylidyne-ammonium,
3-[3-(2,6-dimethyl-phenylamino)-5,7-dimethyl-imidazo-[1,2-a]pyridin-2-yl]-phenol,

(2,6-dimethyl-phenyl)-(8-methyl-2-o-tolyl-imidazo-[1,2-a]pyridin-3-yl)-amine,

{6-[2-(3-hydroxy-phenyl)-8-methyl-imidazo[1,2-a]-pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,

{5-[3-(2,6-dimethyl-phenylamino)-7-methyl-imidazo-[1,2-a]pyrimidin-2-yl]-furan-2-yl}-methanol,

(8-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,

[2-(2,4-dichlorophenyl)-6-methyl-imidazo[1,2-a]-pyridin-3-yl]-(2,6-dimethyl-phenyl)-amine,

butyl-[2-(2,4-dichloro-phenyl)-6-methyl-imidazo-[1,2-a]pyridin-3-yl]-amine,

butyl-[2-(4-dimethylamino-naphthalen-1-yl)-imidazo-[1,2-a]pyrazin-3-yl]-amine,

{6-[2-(2-bromo-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-ylamino]-hexyl}-methylidyne-ammonium,

butyl-[2-(2-methoxy-phenyl)-6-methyl-imidazo[1,2-a]-pyridin-3-yl]-amine,

(2-cyclohexyl-8-methyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine,

cyclohexyl-(7-methyl-2-pyridin-2-yl-imidazo[1,2-a]-pyridin-3-yl)-amine,

cyclohexyl-(2-furan-2-yl-7-methyl-imidazo[1,2-a]-pyridin-3-yl)-amine,

(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-ylamino)-acetic acid methyl ester,

N-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-tert-butyl-N-(7-methyl-2-pyridin-3-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

N-tert-butyl-N-(2-furan-2-yl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

N-(5,7-dimethyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-(5,7-dimethyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-(2,6-dimethyl-phenyl)-N-(5,7-dimethyl-2-o-tolyl-imidazo[1,2-a]pyridin-3-yl)-acetamide,

N-(2-furan-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-(1,1,3,3-tetramethyl-butyl)-N-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-acetamide,

N-cyclohexyl-N-(7-methyl-2-thiophen-2-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

N-tert-butyl-N-(2,5,7-trimethyl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,

5-[3-(acetyl-tert-butyl-amino)-imidazo[1,2-a]pyrazin-2-yl]-thiophene-2-carboxylic acid,

5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl}-furan-2-carboxylic acid,

N-[2-(5-hydroxymethyl-furan-2-yl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-[2-(3-bromo-thiophen-2-yl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide,

N-tert-butyl-N-(2-cyclohexyl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

acetic acid 5-[3-(acetyl-cyclohexyl-amino)-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl]-furan-2-yl methyl ester,

{6-[acetyl-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium,

N-[2-(2,3-dichloro-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide,
N-[2-(3-bromo-thiophen-2-yl)-imidazo[1,2-a]pyridin-3-yl]-N-cyclohexyl-acetamide,
N-(5,7-dimethyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-cyclohexyl-N-(7-methyl-2-pyridin-4-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,
N-cyclohexyl-N-[7-methyl-2-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-(6,8-dibromo-2-furan-2-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-(7-methyl-2-pyridin-4-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
acetic acid 5-[3-(acetyl-cyclohexyl-amino)-7-methyl-imidazo[1,2-a]pyridin-2-yl]-furan-2-yl methyl ester,
N-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-[2-(2,3-dichloro-phenyl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide,
N-cyclohexyl-N-[5,7-dimethyl-2-(5-methyl-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-butyl-N-[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-cyclohexyl-N-[5,7-dimethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-acetamide,
[acetyl-(2,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-amino]-acetic acid methyl ester,

N-cyclohexyl-N-(2,5,7-trimethyl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,
5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-imidazo[1,2-a]pyridin-2-yl}-thiophene-2-carboxylic acid,
N-[2-(2,4-dichloro-phenyl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-cyclohexyl-N-[7-methyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-(2-tert-butyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-acetamide,
N-(2,6-dimethyl-phenyl)-N-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-[2-(3-hydroxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-(2,6-dimethyl-phenyl)-N-[2-(2-fluoro-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,
5-[3-(acetyl-tert-butyl-amino)-5-methyl-imidazo-[1,2-a]pyridin-2-yl]-thiophene-2-carboxylic acid,
N-(2,6-dimethyl-phenyl)-N-[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-(7-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-7-methyl-imidazo[1,2-a]pyridin-2-yl}-furan-2-carboxylic acid,
N-cyclohexyl-N-(7-methyl-2-pyridin-3-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

N-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-(2-benzofuran-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-acetamide,
N-tert-butyl-N-(2-furan-2-yl-7-methyl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,
N-tert-butyl-N-(7-methyl-2-pyridin-2-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,
N-cyclohexyl-N-(5,7-dimethyl-2-pyridin-3-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,
N-[2-(2,3-dichloro-phenyl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-[2-(2,3-dimethoxy-phenyl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-{2-[3-(4-chloro-phenoxy)-phenyl]-imidazo[1,2-a]-pyridin-3-yl}-N-(2,6-dimethyl-phenyl)-acetamide,
N-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
5-[3-(acetyl-cyclohexyl-amino)-5,7-dimethyl-imidazo-[1,2-a]pyridin-2-yl]-furan-2-carboxylic acid,
N-tert-butyl-N-[7-methyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-[2-(2-methoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-[2-(5-methyl-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

5-[3-(acetyl-tert-butyl-amino)-7-methyl-imidazo-[1,2-a]pyridin-2-yl]-furan-2-carboxylic acid,
N-[2-(4,5-dimethyl-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-cyclohexyl-N-(2-furan-2-yl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,
N-tert-butyl-N-(7-methyl-2-naphthalen-1-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,
5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-imidazo[1,2-a]pyrazin-2-yl}-thiophene-2-carboxylic acid,
N-butyl-N-(2-o-tolyl-imidazo[1,2-a]pyrimidin-3-yl)-acetamide,
N-[2-(3,4-dimethoxy-phenyl)-7-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide,
N-tert-butyl-N-(7-methyl-2-phenanthren-9-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,
N-(2,6-dimethyl-phenyl)-N-[2-(2-fluoro-phenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-[2-(2-methoxy-phenyl)-8-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-(2,6-dimethyl-phenyl)-N-[2-(3-hydroxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,
N-(2-tert-butyl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-acetamide,
acetic acid 4-{3-[acetyl-(2,6-dimethyl-phenyl)-amino]-6-bromo-8-methyl-imidazo[1,2-a]pyridin-2-yl}-2-methoxy-phenyl ester,
N-tert-butyl-N-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,

[6-(acetyl-{7-methyl-2-[5-(2-nitro-phenyl)-furan-2-yl]-imidazo[1,2-a]pyridin-3-yl}-amino)-hexyl]-methylidyne-ammonium,
N-(2-benzofuran-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-(2-benzofuran-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
5-[3-(acetyl-tert-butyl-amino)-imidazo[1,2-a]pyridin-2-yl]-thiophene-2-carboxylic acid,
N-(2-cyclohexyl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-tert-butyl-N-[2-(5-methyl-furan-2-yl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide,
N-tert-butyl-N-[2-(5-methylsulfanyl-thiophen-2-yl)-imidazo[1,2-a]pyrimidin-3-yl]-acetamide,
N-[2-(4,5-dimethyl-furan-2-yl)-5-methyl-imidazo-[1,2-a]pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-butyl-N-[2-(2,4-dichloro-phenyl)-imidazo[1,2-a]-pyrimidin-3-yl]-acetamide,
N-[2-(3-bromo-thiophen-2-yl)-6-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-cyclohexyl-acetamide,
5-{3-[acetyl-(2,6-dimethyl-phenyl)-amino]-6-methyl-imidazo[1,2-a]pyridin-2-yl}-thiophene-2-carboxylic acid,
N-butyl-N-[2-(2,3-dimethoxy-phenyl)-7-methyl-imidazo-[1,2-a]pyridin-3-yl]-acetamide,
N-tert-butyl-N-[2-(2,3-dichloro-phenyl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide,
N-(2-furan-2-yl-5-propyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

5-[3-(acetyl-cyclohexyl-amino)-imidazo[1,2-a]pyridin-2-yl]-thiophene-2-carboxylic acid,
5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-8-methyl-imidazo[1,2-a]pyridin-2-yl}-furan-2-carboxylic acid,
3-(acetyl-butyl-amino)-2-pyridin-2-yl-imidazo[1,2-a]-pyridine-8-carboxylic acid,
{6-[acetyl-(5,7-dimethyl-2-pyridin-3-yl-imidazo-[1,2-a]pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium,
N-tert-butyl-N-[2-(5-methylsulfanyl-thiophen-2-yl)-imidazo[1,2-a]pyrazin-3-yl]-acetamide,
5-[3-(acetyl-cyclohexyl-amino)-5-methyl-imidazo-[1,2-a]pyridin-2-yl]-thiophene-2-carboxylic acid,
N-[2-(5-methylsulfanyl-thiophen-2-yl)-imidazo[1,2-a]-pyrazin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
N-[2-(2,3-dichloro-phenyl)-5-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide,
N-butyl-N-[2-(2-methoxy-phenyl)-imidazo[1,2-a]-pyridin-3-yl]-acetamide,
(6-{acetyl-[2-(2-methoxy-phenyl)-6-nitro-imidazo-[1,2-a]pyridin-3-yl]-amino}-hexyl)-methylidyne-ammonium,
N-(2-benzofuran-2-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(2,6-dimethyl-phenyl)-acetamide,
(6-{acetyl-[2-(2-methoxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl]-amino}-hexyl)-methylidyne-ammonium,
{6-[acetyl-(7-methyl-2-pyridin-3-yl-imidazo[1,2-a]-pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium,

N-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
acetic acid 5-{3-[acetyl-(2,6-dimethyl-phenyl)-amino]-5,7-dimethyl-imidazo[1,2-a]pyridin-2-yl}-furan-2-yl methyl ester,
{acetyl-[2-(3-hydroxy-phenyl)-6-methyl-imidazo-[1,2-a]pyridin-3-yl]-amino}-acetic acid methyl ester,
N-tert-butyl-N-[2-(2-trifluoromethyl-phenyl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide,
N-butyl-N-[2-(2-chloro-4-fluoro-phenyl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide,
N-[2-(2,4-dichloro-phenyl)-imidazo[1,2-a]pyridin-3-yl]-N-(2,6-dimethyl-phenyl)-acetamide,
5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-7-methyl-imidazo[1,2-a]pyrimidin-2-yl}-furan-2-carboxylic acid,
acetic acid 5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-imidazo[1,2-a]pyrimidin-2-yl}-furan-2-yl methyl ester,
N-(2,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,
acetic acid 4-[3-(acetyl-cyclohexyl-amino)-5-amino-7-chloro-imidazo[1,2-a]pyrimidin-2-yl]-2-methoxy-phenyl ester,
acetic acid 4-[3-(acetyl-cyclohexyl-amino)-5,7-dimethyl-imidazo[1,2-a]pyrimidin-2-yl]-2-methoxy-phenyl ester,
N-[6-bromo-2-(2-chloro-6-fluoro-phenyl)-8-methyl-imidazo[1,2-a]pyridin-3-yl]-N-cyclohexyl-acetamide,
N-[2-(2-chloro-6-fluoro-phenyl)-5-methyl-imidazo-[1,2-a]pyridin-3-yl]-N-cyclohexyl-acetamide,

N-butyl-N-[2-(2,3-dichloro-phenyl)-imidazo[1,2-a]-pyrimidin-3-yl]-acetamide,

N-[2-(5-chloro-thiophen-2-yl)-imidazo[1,2-a]-pyrimidin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

[acetyl-(2-cyclohexyl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-amino]-acetic acid methyl ester,

N-tert-butyl-N-[2-(2-chloro-6-fluoro-phenyl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide,

N-cyclohexyl-N-(5,7-dimethyl-2-pyridin-2-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

acetic acid 5-[3-(acetyl-cyclohexyl-amino)-5-methyl-imidazo[1,2-a]pyridin-2-yl]-furan-2-yl methyl ester,

N-(2,6-dimethyl-phenyl)-N-[6-methyl-2-(2-trifluoro-methyl-phenyl)-imidazo[1,2-a]pyridin-3-yl]-acetamide,

N-cyclohexyl-N-(2-furan-2-yl-7-methyl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,

N-cyclohexyl-N-(7-methyl-2-pyridin-2-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

N-cyclohexyl-N-[2-(5-[1,3]dioxolan-2-yl-furan-2-yl)-5-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,

N-tert-butyl-N-(5-propyl-2-pyridin-3-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

N-tert-butyl-N-[2-(5-methyl-thiophen-2-yl)-imidazo-[1,2-a]pyrimidin-3-yl]-acetamide,

3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-2-furan-2-yl-imidazo[1,2-a]pyridine-8-carboxylic acid,

N-tert-butyl-N-[2-(4,5-dimethyl-furan-2-yl)-6-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,

N-{2-[3-(4-chloro-phenoxy)-phenyl]-imidazo[1,2-a]-pyridin-3-yl}-N-cyclohexyl-acetamide,

acetic acid 4-[3-(acetyl-cyclohexyl-amino)-imidazo-[1,2-a]pyrimidin-2-yl]-2-methoxy-phenyl ester,

N-[2-(5-bromo-furan-2-yl)-8-methyl-imidazo[1,2-a]-pyridin-3-yl]-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-(2,6-dimethyl-phenyl)-N-[2-(3-hydroxy-phenyl)-5,7-dimethyl-imidazo[1,2-a]pyrimidin-3-yl]-acetamide,

N-cyclohexyl-N-[2-(2,3-dichloro-phenyl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide,

N-cyclohexyl-N-[2-(2,4-dichloro-phenyl)-5-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,

N-cyclohexyl-N-[2-(2,4-dichloro-phenyl)-imidazo-[1,2-a]pyrimidin-3-yl]-acetamide,

[acetyl-(2-o-tolyl-imidazo[1,2-a]pyrazin-3-yl)-amino]-acetic acid methyl ester,

N-tert-butyl-N-(6,8-dichloro-2-thiophen-2-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

N-tert-butyl-N-(5-propyl-2-thiophen-2-yl-imidazo-[1,2-a]pyridin-3-yl)-acetamide,

{6-[acetyl-(7-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium,

N-butyl-N-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-acetamide,

(6-{acetyl-[2-(2-methoxy-phenyl)-7-methyl-imidazo-[1,2-a]pyridin-3-yl]-amino}-hexyl)-methylidyne-ammonium,

5-{3-[acetyl-(1,1,3,3-tetramethyl-butyl)-amino]-6-methyl-imidazo[1,2-a]pyridin-2-yl}-furan-2-carboxylic acid,

N-butyl-N-[2-(3,4,5-trimethoxy-phenyl)-imidazo-[1,2-a]pyrazin-3-yl]-acetamide,

N-butyl-N-[2-(3-hydroxy-phenyl)-imidazo[1,2-a]-pyrimidin-3-yl]-acetamide,

[acetyl-(2-o-tolyl-imidazo[1,2-a]pyrimidin-3-yl)-amino]-acetic acid methyl ester,

N-(2-benzofuran-2-yl-8-methyl-imidazo[1,2-a]pyridin-3-yl)-N-(1,1,3,3-tetramethyl-butyl)-acetamide,

N-butyl-N-(7-methyl-2-p-tolyl-imidazo[1,2-a]-pyrimidin-3-yl)-acetamide,

N-tert-butyl-N-(6,8-dibromo-2-methyl-imidazo[1,2-a]-pyridin-3-yl)-acetamide,

{6-[acetyl-(5,7-dimethyl-2-pyridin-2-yl-imidazo-[1,2-a]pyridin-3-yl)-amino]-hexyl}-methylidyne-ammonium,

N-tert-butyl-N-[2-(2-ethoxy-naphthalen-1-yl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide,

N-tert-butyl-N-[2-(2-chloro-4-fluoro-phenyl)-imidazo-[1,2-a]pyridin-3-yl]-acetamide,

cyclohexyl-[7-methyl-2-(2-trifluoromethyl-phenyl)-imidazo[1,2-a]pyridin-3-yl]-amine hydrochloride,

tert-butyl-(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine hydrochloride,

tert-butyl-(7-methyl-2-phenyl-imidazo[1,2-a]pyridin-3-yl)-amine hydrochloride,

cyclohexyl-(5,7-dimethyl-2-pyridin-4-yl-imidazo-[1,2-a]pyridin-3-yl)-amine hydrochloride,

(2-furan-2-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride,

tert-butyl-(2,5,7-trimethyl-imidazo[1,2-a]pyridin-3-yl)-amine hydrochloride,

[2-(2-fluorophenyl)-7-methyl-imidazo[1,2-a]pyridin-3-yl]-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride,

cyclohexyl-(7-methyl-2-phenyl-imidazo[1,2-a]pyridin-3-yl)-amine hydrochloride,
(2-furan-2-yl-7-methyl-imidazo[1,2-a]pyrimidin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride,
tert-butyl-[2-(4-nitro-phenyl)-imidazo[1,2-a]pyrazin-3-yl]-amine hydrochloride,
N-{2-[3-(4-chlorophenoxy)-phenyl]-imidazo[1,2-a]-pyridin-3-yl}-N-cyclohexyl-acetamide hydrochloride,
N-cyclohexyl-N-(7-methyl-2-o-tolyl-imidazo[1,2-a]-pyridin-3-yl)-acetamide hydrochloride,
N-(2,6-dimethyl-phenyl)-N-[2-(2,4-dimethyl-phenyl)-5-methyl-imidazo[1,2-a]pyridin-3-yl]-acetamide hydrochloride,
1-acetyl-3-(acetyl-cyclohexyl-amino)-7-methyl-2-o-tolyl-imidazo[1,2-a]pyridin-1-ium) chloride hydrochloride,
cyclohexyl-(2-furan-3-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine hydrochloride,
cyclopentyl-(2-furan-3-yl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-amine hydrochloride,
[2-(4-bromo-2-fluoro-phenyl)-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl]-cyclopentyl-amine hydrochloride,
cyclopentyl-{5,7-dimethyl-2-[5-(2-nitro-phenyl)-furan-2-yl]-imidazo[1,2-a]pyridin-3-yl}-amine hydrochloride,
{2-[5-(4-chlorophenyl)-furan-2-yl]-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl}-cyclopentyl-amine hydrochloride,
cyclopentyl-(2-furan-3-yl-5,7-dimethyl-imidazo-[1,2-a]pyridin-3-yl)-amine hydrochloride,
(2-furan-3-yl-5,7-dimethyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride,

benzyl-(7-methyl-2-thiophen-3-yl-imidazo[1,2-a]-pyridin-3-yl)-amine hydrochloride,
cyclohexyl-(2-furan-3-yl-5,7-dimethyl-imidazo[1,2-a]-pyridin-3-yl)-amine hydrochloride,
(2-furan-3-yl-7-methyl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride,
(5,7-dimethyl-2-thiophen-3-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-tetramethyl-butyl)-amine hydrochloride,
[7-ethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]-pyridin-3-yl]-(2-methoxybenzyl)-amine,
(2-chlorobenzyl)-[7-ethyl-2-(5-nitro-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-amine,
[7-ethyl-2-(5-methyl-furan-2-yl)-imidazo[1,2-a]-pyridin-3-yl]-(2-methoxy-benzyl)-amine,
(2-chlorobenzyl)-(7-ethyl-2-furan-2-yl-imidazo-[1,2-a]pyridin-3-yl)-amine,
(3-chloro-4-fluorophenyl)-[7-ethyl-2-(5-methyl-furan-2-yl)-imidazo[1,2-a]pyridin-3-yl]-amine,
(2-benzofuran-2-yl-7-ethyl-imidazo[1,2-a]pyridin-3-yl)-(3-chloro-4-fluorophenyl)-amine,
(2-benzofuran-2-yl-7-ethyl-imidazo[1,2-a]pyridin-3-yl)-(3-chlorophenyl)-amine,
(3-chloro-4-fluorophenyl)-{2-[5-(3-chloro-phenyl)-furan-2-yl]-7-ethyl-imidazo[1,2-a]pyridin-3-yl}-amine,
(3-chloro-4-fluorophenyl)-{2-[5-(2-chlorophenyl)-furan-2-yl]-7-ethyl-imidazo[1,2-a]pyridin-3-yl}-amine,
(3-chloro-4-fluorophenyl)-[2-(4,5-dimethyl-furan-2-yl)-7-ethyl-imidazo[1,2-a]pyridin-3-yl]-amine.

Fetherstonhaugh & Co.
Ottawa, Canada
Patent Agents